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ABSTRACT
Huang, Wanfeng. Ph.D., Purdue University, December 2016. Concurrent Detection and
Isolation of Cellular and Molecular Biomarkers. Major Professor: Çağrı Savran, School of
Mechanical Engineering.
Detection of cancer markers such as protein biomolecules and cancer cells in bodily
fluids is of great importance in early diagnosis, prognosis as well as evaluation of therapy
efficacy. Numerous devices have been developed for detecting either cellular or molecular
targets, however there has not yet been a system that can simultaneously detect both
cellular and molecular targets effectively. Molecule and cell-based assays are important
because each type of target can tell a different story about the state of the disease and the
two types of information can potentially be combined and/or compared for more accurate
biological or clinical assessments. Therefore, the primary goal of the thesis is to develop a
system that can simultaneously measure both cellular and molecular biomarkers from one
and the same sample. With its high sensitivity and high-throughput capability, this system
can capture rare cells such as circulating tumor cells (CTCs) from human bodily fluids (e.g.
blood, ascites). Moreover, the system enables post-detection analysis of captured targets
and can be compatible with established screening tools. In this thesis two generations of
the system have been developed to achieve these goals.

xiv
The first-generation system is based on a single-layer fluidic chamber. Free magnetic
beads conjugated with antibodies against a specific antigen are used to isolate both free
molecules and whole cells overexpressing an antigen. The captured cells and molecules are
quantitatively analyzed together on the same device surface using fluorescent microscopy.
The system was first numerically modeled, and then experimentally characterized by
simultaneously detecting free folate receptor (FR), and an FR+ cancer cell line (KB) that
were added into cell culture medium with known number. This system was further
validated by detecting KB cells and FR spiked into healthy human blood to simulate
detection of CTCs and protein biomarkers present in cancer patient blood. The potential of
this approach in clinical diagnostics was also demonstrated by detecting both FR+ cells
and FR in an ascites sample obtained from an ovarian cancer patient.
The second-generation system employs a similar detection strategy but integrates a
micro-aperture chip into the fluidic chamber to sort cells and molecules (including free
beads) into different layers based on their sizes, which significantly reduces mutual
interference and improves detection efficiency including detection yield and repeatability.
Moreover, large number of beads can be used to further increase cell detection yield. The
system was first characterized by detecting rare cells spiked in both cell culture medium
and health human blood and applied for CTC detection from cancer patients’ blood samples.
Then the system was further developed for separation and simultaneous detection of both
model molecular and cellular prostate cancer markers (namely the prostate-specific
membrane antigen (PSMA), LNCaP cells) from both culture medium and blood.
Finally, a post-detection application was demonstrated by culturing the cells that were
detected and retrieved by our second-generation system. Future work will be focused on

xv
gene sequencing of captured rare cells, screening of cancer patient blood samples for dual
detection of molecules as well as cells, and integration of novel capture ligands.
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CHAPTER 1. INTRODUCTION
1.1

Motivation

Detection of biomarkers is of great significance in numerous biomedical fields including
diagnosis, prognosis, therapeutic evaluation, as well as in pharmacodynamics studies and
cell identification [1-3]. Biomarkers include a wide variety of molecules such as small
analytes (e.g. hormones, metabolites, etc.), larger biomolecules (e.g. DNA/RNA, proteins,
etc.) as well as cells themselves [4-9]. It has been shown that biomarkers have numerous
advantages and offer great potential, however, barriers and limitations have reduced their
real-life utility [1, 2, 10-12]. Inter-individual variability, reliability, sensitivity and
specificity have led to measurement deviations which become exacerbated when only a
single biomarker is used. As a result, multiple platforms are often employed to perform
numerous biomarker tests, often at great expense, in order to provide sufficient and reliable
information for patient evaluation [13-16].
In cancer research and diagnostics, cells and proteins are the most common entities to
be detected [17-20]. During the past decade, circulating tumor cells (CTCs) have been
extensively studied and validated as a prognostic tool in prostate cancer [21, 22]. CTCs are
shed from both primary and metastatic tumors and circulate in the blood of cancer patients.
CTCs have the potential to serve as indicators of metastatic disease and possibly recurrence
after surgery in some tumor types [4-7, 23]. They are very scarce (as few as 1 or less per
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mL of blood sample as opposed to some 10 million normal white blood cells and 100
million red blood cells per 1 mL of blood) thus large sample volume (~7.5 mL) is necessary
for reliable analysis.
On the other hand, protein biomarkers in serum can reveal information about the onset
and progression of many diseases ranging from heart failure to cancers [8, 9]. Serum
proteins such as prostate specific antigen (PSA), epidermal growth factor receptor (EGFR)
and carcinoembryonic antigen (CEA) have been approved by US Food and Drug
Administration (FDA) as cancer biomarkers [9]. Meanwhile, continuous efforts are being
placed on searching novel protein biomarkers. For example, many studies show that folate
receptor (FR) or folate binding protein (FBP), a glycosylphosphatidylinositol-linked
protein, is a biomarker for several epithelial malignancies [24-26]. It has been shown that
ovarian cancer patients have elevated serum levels of FR alpha, which is over-expressed
on the surfaces of malignant cells which can eventually shed into the blood [27].
Despite the advances in detecting molecules and cells, to our best knowledge, there has
not been a system capable of effectively detecting both of these markers at the same time
and from the same sample. Although it is possible to adapt some molecular detection
platforms to detect whole cells, and vice versa, most platforms are optimized and
configured for detection of either molecules or cells but not both. Often, multiple devices
are used to perform each test separately, at different times, and/or with different samples.
For example, Pierga et al. investigated the prognostic and predictive value of CTCs in
chemotherapy for metastatic breast cancer patient by means of a comparison with serum
tumor markers (e.g. CEA, CA15-3 and lactate dehydrogenase) [28]. Hou et al. evaluated
both CTCs and serological cell death biomarkers as blood assays of small lung cancer
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patients undergoing chemotherapy [29]. Davis et al. studied the correlation between CTCs
in peripheral blood samples from prostate cancer patients and their serum levels of prostate
specific antigen [30]. In their studies, patient samples (e.g. blood, ascites) were first
collected separately and then screened by multiple tools such as enzyme-linked
immunosorbent assays (ELISA) to quantify molecular markers and CellSearch system to
quantify the CTCs. A major and obvious limitation in performing molecular and cellular
analyses at different times, different samples and different platforms is the variation among
samples themselves and/or the experimental conditions such as temperature, incubation
period, chemical reagents used to preprocess the sample by each different platform and so
on [28-30].
This thesis study aims to develop a system capable of concurrently detecting both cellular
and molecular markers from one sample. In addition to overcoming the shortcomings
discussed in previous paragraph, this system has the capability to analyze large volumes of
sample to efficiently capture rare cells (e.g. CTCs) and biomolecules (e.g. serum cancer
markers). We expect that detecting both cells and molecules should provide more complete
information (e.g. regarding tumor stage, metastasis, treatment evaluation) than detecting
only proteins or only cells, and potentially enable newer and more useful analyses. Finally,
the new system can retrieve captured cells and molecules for subsequent analysis, which
can further lead to the discovery of new mutations and expand our understanding of cancer
biology via DNA/RNA sequencing [19, 31, 32].
1.2

Current Systems for Cell Detection

Isolating cells from biological fluids has always been important for a number of fields
such as cell biology, physiology, medicine and pathology [33-36]. For example,
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detection/isolation of circulating tumor cells (CTCs) has the potential for prediction of
treatment efficacy and possibly early detection of cancer, and hence has received
significant attention in recent years [4-7].
Cell sorting techniques are routinely applied to separate cells of interest from
heterogeneous suspensions [37]. There are many methods currently available for rare cell
detection and isolation. Examples of some commonly seen methods and systems will be
described and discussed in the following sections.
1.2.1

Fluorescence-activated Cell Sorting (FACS)

Fluorescence-activated cell sorters (FACS), e.g. flow cytometry (Figure 1.1), are widely
used in biomedical research and clinical diagnostics. These tools greatly facilitate the study
of both physical properties (e.g., size, shape) and biochemical properties (e.g., cell cycle
distribution, DNA contents) of biological particles such as cells. Information regarding the
cells that pass through the device is acquired optically in a nondestructive and quantitative
manner. After signal-reading, the cells of interest are immediately labeled with an electrical
polarization that is the opposite of that of the other cells, then the labelled cells are deflected
into a collection zone using an electrical force. This method can automatically sort out and
analyze cells of interest. However, because of the serial nature of its operation, FACS is
limited to a comparatively low throughput especially when a large sample volume (e.g. 7.5
mL) is processed [37, 38]. FACS is most effective for analyzing thousands to millions of
cells in a mL (as opposed to rare cells that present themselves much more scarcely: 1 cell
per mL or less). This costly system is quite complicated and prone to practical problems
such as clogging, and requires highly trained lab personnel for operation [39].
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Figure 1.1. Schematic of Fluorescence-activated cell sorting [40].
1.2.2

Magnetically Activated Cell Sorting (MACS)

The MACS method separates cells by incubating them with magnetic particles coated
with antibodies against a particular surface antigen. Cells expressing this antigen attach to
the magnetic nanoparticles. Following that the cell suspension is transferred to a column
placed in a magnetic field. In this step, the cells conjugated with the magnetic particles as
well as the particles that have not bound to any cells stay on the column, while other cells
(not expressing the antigen) flow through. With this method, the cells can be sorted out
with respect to the particular antigen. This simple method is used for capturing of the cells
but not their detection. Hence, once the cells are sorted, they are mostly used in conjunction
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with a detection platform such as FACS. The manual MACS columns are commercially
available by providers such as Miltenyi Biotec.
Researchers have also developed sophisticated and advanced systems based on the
MACS principle. Professor Soh's group at UC Santa Barbara reported a magnetically
activated cell sorter (MACS), which makes use of microfluidics technology to sort multiple
types of target cells in a continuous-flow manner [41]. They used the MACS device to
purify 2 types of target cells, which had been labeled via target-specific affinity reagents
with 2 different magnetic tags with distinct saturation magnetization and size (Figure 1.2).
The device was engineered so that the combined effects of the hydrodynamic force
produced by the laminar flow and the magnetophoretic force produced by the patterned
ferromagnetic structures within the microchannel result in the selective purification of the
differentially labeled target cells into multiple independent outlets [41].
This sophisticated system has well defined requirements for the size, shape and
magnetization of the magnetic tags to achieve a balance between the functional magnetic
force and the fluidic drag force. These requirements increase the overall complexity and
the fabrication cost. Also, large sample volume (e.g. 7.5 mL of patient blood) is often
necessary for rare cell detection. However, the volumetric flow rate that can be achieved
with such devices is around 5 mL/h, which makes the analysis of large sample volumes
challenging.
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Figure 1.2. Schematic of magnetic-activated cell sorting [41].
1.2.3

Other Microfluidic Methods

A number of groups have developed cell sorting systems that employ microfluidics in
various forms. Here we only focus on the system that we believe is the most advanced
system developed so far. Professor Toner's group developed a strategy that combines
microfluidics for rare cell handling while incorporating the benefits of magnetic-based cell
sorting (e.g. high sensitivity and purity, easy to be operated) [7]. After magnetically
labeling cells in whole blood, their capture platform integrates three sequential microfluidic
components (Figure 1.3) within a single automated system: (i) separating nucleated cells,
including CTCs and white blood cells (WBCs), from red blood cells (RBCs) and platelets
using deterministic lateral displacement; (ii) alignment of nucleated cells into a single file
within a microfluidic channel using inertial focusing; and (iii) deflection of magnetically
tagged cells into a collection tube.
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Figure 1.3. Schematic of inertial focusing for cell separation [7].
The advantage of this platform is that the three integrated microfluidic functions replace
bulk RBC lysis and/or centrifugation, hydrodynamic sheath flow in flow cytometry, and
conventional magnetic-activated cell sorting (MACS). However, it still has shortcomings
such as system complexity, relatively high fabrication cost as well as vulnerability to
bubbles, which may hinder the device operation and damage the targeted cells.
Based on the review of the currently available techniques for cell detection, a brief
conclusion could be drawn here that there are limitations in terms of volumetric flow rate
(i.e. volumetric throughput), system complexity, operation difficulty, fabrication cost, as
well as robustness. Our ultimate goal is to develop a system that not only mitigates the
above-mentioned shortcomings but also allows concurrent detection of both cells as well
as molecules which cannot be effectively performed by the aforementioned methods.
Therefore, the next section (1.3) will present a review of the state of the art on technologies
that only perform biomolecular screening.
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1.3

Current Systems for Biomolecular Detection

As mentioned before, detecting molecular biomarkers is also important in disease
diagnosis, prognosis and therapy. We will therefore discuss biomolecular screening assays
in this section.
There are numerous biomolecule screening approaches, which can be classified into three
categories including methods that use labels (e.g. enzyme-linked immuno-sorbent assays
(ELISAs)), label-free methods (e.g., surface plasma resonance (SPR), quartz crystal
microbalance (QCM)), as well as MEMS-based techniques such as microcantilever
deflection, grating diffraction-based biosensors and magnetic nanosensors [42-47]. The
methods in the latter category may overlap with label-based or label-free methods to a
certain degree, in that they may or may not use labels. We however chose to place them in
a separate category since they are different from mainstream commercial label-based and
label-free platforms, owe their existence to advances in micro and nanotechnology and are
still in the research phase. Since the primary goal of this thesis is to realize concurrent
detection of cellular and molecular targets rather than pushing the limits of one particular
biosensor, we mainly focused on commercially available systems and summarize them
below.
1.3.1

Label-based Methods

Label-based methods depend on the use of molecular labels covalently attached to the
biomolecules of interest to facilitate detection of the labeled biomolecules. Enzyme-linked
immunosorbent assays (ELISAs), in various forms are the gold standard of biomolecular
detection today. They are plate-based assays designed for detecting and quantifying
substances such as peptides, proteins, antibodies and hormones. Typically, an ELISA assay
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is designed for single analyte measurement. Among various forms of ELISAs, sandwich
ELISAs is used to detect sample antigens. In a sandwich ELISA (Figure 1.4), a plate is first
coated with a capture antibody; sample is then added so that antigens present can binds to
the capture antibody. Following that, detection antibody is added, and binds to the antigen.
Next, enzyme-linked secondary antibody is added which binds to the detection antibody.
Finally, a substrate is added, which is converted by the enzyme to a detectable form [48].
Sandwich ELISAs allow biomolecules to be detected at low concentrations (pico-molar).
A disadvantage is that the readout of ELISAs involves multiple antibodies which adds
complexity to the assay. Also like any platform that uses a fluorescent or colorimetric signal
for detection, inherent autofluorescence or optical absorption of the matrix or reagents can
lead to errors [47].

Figure 1.4. Schematic of a basic ELISA assay [48].
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Besides the single-analyte measurement techniques, there has been developments in
multiple biomolecular analyte detection. Multiplex assays invented by Luminex
Technology use bead-based flow cytometry to detect and sort multiple analytes
simultaneously. This technique performs a sandwich immunoassay using magnetic beads
that have internal dyes to achieve capture, separation and quantification of multiple classes
of biomolecules at the same time (Figure 1.5). However, Luminex multiplex technology
still has disadvantages which are common to multiplex assays such as possible crossreactivity between antibodies. Sensitivity may also be compromised when increasing
number of beads has to be used for multi-target detection [49]. Moreover, Luminex
technology is not cost-effective compared to normal bead-based assays which does not
need specialized color-coated beads.

Figure 1.5. Schematic graph of the multiplex Luminex assay. Note: in step 1-4, only one
bead is shown to capture one type of analyte; in step 5, multiple color-coated beads were
screened and profiled according to their color codes.
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1.3.2

Label-free Methods

As opposed to label-based techniques, label-free methods detect targets without requiring
any type of radio, enzymatic- or fluorescent-labelling to report the binding event. The
general advantages of label-free techniques are real-time monitoring of binding events,
elimination of labelling procedures which cuts down on cost, as well as direct information
from the target (as opposed to information from a tag that is attached to the target) [50]. A
disadvantage of these systems is that non-specific binding effects at the sensor surface must
be carefully controlled [51, 52]. Another problem is to ensure that the transfer of the analyte
to the ligand at the sensor surface is not limited, otherwise the analyte concentration near
the surface may be different from the bulk concentration (referred to as mass transport
limitation) [53]. There are various types of label-free methods, among which surface
plasmon resonance and quartz crystal microbalance are typical techniques for biomolecule
screening.
Surface plasmon resonance (SPR): SPR is the resonant oscillation of electrons at the
interface between a negative and positive permittivity material stimulated by incident light
[54]. As shown in Figure 1.6, the metal chip (silver or gold) is prepared with a dextran
surface which can conjugate protein to the metal surface. At the bottom a single wavelength
laser beam enters a prism which results in lights with multiple angles striking the metal
surface. The light with specific angle will be absorbed by the metal and its energy will be
turned to a plasmon wave onto the outer surface of the metal. At this angle, no light is
reflected and thus appears with very little intensity on the detector. Since the plasmon wave
propagates on the outer side of the metal, any interaction with the conjugated protein will
change the resonance angle [55]. Generally, the resonance condition is achieved when the
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frequency of incident photons matches the natural frequency of surface electrons
oscillating against the restoring force of positive nuclei, and the natural frequency is a
function of the amount of targets attached to the device surface. One fundamental problem
is that SPR cannot perform high-throughput detection. The typical sample volume is
around 100 µL, which is a major limiting factor when large volume (e.g. 7.5 mL) analysis
is required. Also, SPR assays are usually performed in clear buffer solutions and are
difficult to operate in complex media such as blood.

Figure 1.6. Scheme of surface plasmon resonance [55].
Quartz crystal microbalance (QCM): As opposed to the SPR which measures optical
signals, a QCM measures mass added onto the sensing surface. To be more specific, “mass
per unit area” is measured by monitoring the change in the frequency of a quartz
crystal resonator as a function of mass absorption onto crystal surface (Figure 1.7) [56].
The resonance is perturbed by the addition or removal of a small mass due to molecular
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binding at the surface of the acoustic resonator. In addition to those common limitations
(e.g. non-specificity) with label-free techniques, a QCM must be operated under wellcontrolled conditions such as quartz plate thickness, density of quartz and temperature [57].
For example, the temperature of the setup must be very precisely controlled as this will
significantly influence the resonance frequency of the quartz crystal [58].

Figure 1.7. Schematic of quartz crystal microbalance. The QCM measures mass changes
on the sensor chip. A sensor, the key of QCM, oscillates at a specific frequency when
voltage is applied. The frequency of the oscillation is dependent on the mass on the
sensor due to adsorption or binding of molecules.
Cantilever sensors: Researchers have explored other state-of-the-art sensing modalities
enabled by the technological advances in micro and nanofabrication particularly over the
last decade. The Manalis group at MIT reported label-free protein detection using a
microfabricated cantilever-based sensor (Figure 1.8). The cantilever surface was
functionalized with DNA aptamers to act as receptor molecules [59]. Upon binding of
target analytes, a change in surface stress causes the cantilever to bend. The dual-beam
cantilever configuration constituted a sensor/reference pair and enables direct detection of
the differential bending between the two cantilevers using the diffraction of a laser beam.
Cantilever sensor realizes label-free detection, but requires precise control of laser power,
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and other experimental conditions. Also, the lack of physical understanding of the
relationship between the molecular binding and the resulting surface stress makes
quantification difficult.

Figure 1.8. Schematic of the cantilever-based sensor. Aptamers were immobilized onto
the sensor surface as molecule receptors to bind ligands of interest. The differential
bending is measured directly using interferometry.
The goal of this thesis study is to develop a novel platform that can detect both cells and
molecules. Hence, an appropriate molecular detection modality that can be integrated into
the same package that performs cell detection is needed. Such a modality should either be
selected from the available ones or be invented from scratch. We therefore summarize
below the molecular detection platforms in this context.
All of the biomolecular sensors and platforms that have been discussed in sections 1.3.1
to 1.32 have their advantages as well as limitations. Some systems (e.g. ELISA) show great
performance in limit of detection (LOD) but are difficult to realize outside their dedicated
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hardware (i.e. 96-well plates and plate readers) and standardized amplification reagents
which also make it challenging to adapt these systems to the analysis of large volumes of
samples (i.e. limited throughput). Some systems (e.g. SPR, QCM) have the capability of
label-free screening and hence do not require as many or any reagents needed by ELISA,
but only at the expense of lower resolution, which is the main reason why label-based
techniques still constitute the gold standard in molecular detection. Also these platforms
are designed mostly to analyze small volumes of samples and hence are not directly
amenable for high volumetric throughput detection. We seek to develop a system that can
target rare entities, hence being able to analyze relatively large, multi-milliliters of sample
volumes. Hence, being able to perform high-volumetric throughput detection is critical to
a system that aims to process 7.5 mL or more sample volume (this is the volume of a typical
blood sample collected in a hospital lab). The Luminex multiplex assay does show good
performance in all those areas. The Luminex technology can be configured to either cell
sorting or protein screening. It however cannot quantitatively detect the two targets at the
same time. Further, the specialized beads (that are inherently fluorescent) used by the
Luminex system limit its versatility and adds to its cost.
1.4

Concurrent Detection of Cellular and Molecular Targets

As mentioned before, most biosensing systems are mainly developed to detect only one
type of a target: either molecules or cells but not both. It is possible to use these systems to
detect both types of targets but it requires a significant amount of modification and
optimization of experimental conditions and procedures to switch from one mode to the
other. This thesis presents a system that can simultaneously capture and analyze both cells
and protein biomolecules present in a sample fluid. The system has excellent capability to
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process large sample volumes in a short time. Also, large amount of sensing substrates as
well as multiple ligands can be integrated to further improve detection yield. Lastly,
captured cells can be retrieved for downstream analysis while advanced protein screening
tool can be integrated for high-performance detection. In this new system magnetic
particles functionalized with antibodies against target biomolecules as well as surface
antigens on target cells are used to capture the two targets (Figure 1.9). Bead-bound cells
and bead-bound molecules are then pumped into a fluidic device where a permanent
magnet is placed beneath the device to capture magnetic particles and any target entities
bound to them.

Figure 1.9. Scheme of dual-target detection.
Two generations of the systems have been developed. A single-layer fluidic device (first
generation system) was first developed, in which cellular and molecular targets were
captured and analyzed together on its glass surface. As we will also describe later, due to
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the inability of the system to 1) separate one type of analyte from the other (even though it
can detect them) and 2) process large number of beads, first generation system had limited
efficiency in targeting more than one analyte.
To achieve higher detection efficiency as well as better compatibility with other
downstream applications and standard laboratory equipment, the second-generation device
was developed. This upgraded system is a combination of immunomagnetic separation and
size-based filtration. It consists of a dual-layer microfluidic device wherein a microaperture chip was inserted as the interface between the top and the bottom chambers. By
virtue of the micro-aperture chip, beads attached with target molecules, owing to smaller
size (1~2 um), are drawn down to the bottom chamber through the holes, while the target
cells bound with beads are retained on the chip surface. There are multiple advantages of
micro-aperture system over the single-layer system. Lager number of beads can be used to
realize multiplex assay as well as to increase cell detection yield. Moreover, even though
it is not within the scope of this thesis study, this system can be adapted with commercial
assays such as Luminex by directly replacing magnetic beads with color-coated magnetic
beads. Post-detection analysis could be another potential benefit of using the concurrent
detection system in cell-relevant studies. For example, subsequent analysis of recovered
captured rare cells can further lead to the discovery of new mutations and expand our
understanding of cancer biology via DNA/RNA sequencing [19, 31, 32].
1.5

Thesis Organization

The first-generation device, a single layer fluidic system, is presented in Chapter 2. The
forces within the system were modeled numerically for simulating the particle trajectories
to understand favorable operating conditions. The system was characterized in terms of its
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response to free protein concentration, as well as its yield in detecting cells spiked in
complex mixtures. To demonstrate the system’s potential in clinical applications, we
detected free FR and KB cells spiked into healthy human blood, as well as endogenous FR
and FR+ cells present in the ascites obtained from an ovarian cancer patient.
In Chapter 3, the development of the second-generation device, which employs a microaperture chip that was embedded to sort cellular targets, is presented. Even though the
ultimate goal of this thesis is to develop a system that can detect both cells and molecules,
this chapter focuses on the cell-detection aspect of the device. System design, device
fabrication and assembly, modeling (i.e. cell capture yield, working mode), as well as
characterization of the system with respect to detection and isolation of CTCs are discussed
successively. Finally, on-chip detection of CTC numbers from actual cancer patient blood
are demonstrated.
The improved version of the device presented in Chapter 3, i.e. the dual cellular and
molecular detection system is the topic of Chapter 4. Separation and dual detection of
prostate cancer cell and molecular molecule biomarkers is discussed. This chapter begins
with system and device assembly and numerical modeling, which is followed by
characterization of the system in separation and dual detection of the two targets spiked
culture medium and healthy human blood. Detection and isolation of the model prostate
cancer tumor cells (LNCaP cells) and prostate cancer molecular markers (PSMA) from the
same sample fluid is presented in this chapter.
In Chapter 5, post-detection applications such as cultivation of captured cells (e.g. CTCs)
for future analysis is present first. Potential for future work, which will be focused on single
cell manipulation (e.g. selectively picking up single cells with a pipette-syringe
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manipulator), dual detection of cells and molecules from cancer patient blood, as well as
integration of novel ligands for CTC detection are discussed.
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CHAPTER 2. FIRST-GENERATION SYSTEM

2.1

Introduction

This chapter presents a basic device that can capture and detect cells and molecules
of interest in a complex fluidic mixture. In this first-generation system, magnetic
particles functionalized with antibodies against target biomolecules as well as
surface antigens on target cells are used. However, the peripheral fluidic,
sample/waste collector, permanent magnet, and other experimental components are
intentionally simple to demonstrate the proof-of-concept. The bead-bound targets
(both proteins and cells) are captured magnetically on the surface of a glass slide
(which constitutes the “chip” of the first-generation system) under high volumetric
flow rates (2-3 mL/min). High volumetric flow rate is necessary for processing large
sample (~7.5 mL) in order to capture rare cells with a concentration of less than 10
per mL. The method is versatile enough that beads conjugated with a variety of
antibodies can be combined to target various molecular targets and cell surface
antigens. The method becomes especially simple for applications wherein the free
biomolecular target is also overexpressed on the target cell surface, e.g. free prostate
specific membrane antigen (PSMA) and PSMA+ tumor cells, and free epidermal
growth factor (EGFR) and EGFR+ tumor cells. Chapter 2 mainly focuses on
detecting free folate receptor (FR) and FR+ tumor cells. Folate (vitamin 9 or pteroyl-
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carbon pathways [60]. FR, also known as folate-binding protein, captures folate and
mediates delivery of folate to the interior of cells. Both normal epithelial cells and
carcinomas express FR to some extent, however epithelial-derived tumor (e.g. ovarian,
breast, renal, lung, colorectal, and brain) cells overexpress FR [61, 62]. Thus, a number of
studies showed that FR is a biomarker for several epithelial malignancies [24-26]. It has
also been shown that ovarian cancer patients have elevated serum levels of FR alpha, which
is over-expressed on the surfaces of malignant cells and eventually shed into the blood as
free FR [27].

The detection strategy is illustrated in Figure 2.1. Superparamagnetic particles are
first conjugated with polyclonal antibodies against FR (anti-FR). These anti-FR
beads are then introduced into a sample fluid containing FR and FR+ cells for
incubation (Figure 2.1 (a)). The incubated sample mixture then flows through a
fluidic chamber made of a PDMS channel and two glass slides (Figure 2.1 (b)).
During the flow, target cells and molecules are attracted to the surface of the bottom
glass (the chip) slide in a magnetic field generated by a magnet placed beneath the
chamber, while other entities in the sample fluid are washed away under a high
volumetric flow (~3 mL/min). Finally, captured targets are quantitated using
fluorescence microscopy (Figure 2.1 (c)).

23

Figure 2.1. Schematic showing the operation principles. (a) FR molecules and FR+ KB
cells bound to anti-FR beads; (b) Microfluidic chamber designed for immunomagnetic
detection of KB cells and free FR: KB cells and FR are simultaneously captured by the
magnetic field as the sample fluid flows through the chamber; (c) Bright-field (c.1) and
fluorescent (c.2) images obtained from the same detection surface. White arrows point to
the captured cells.

24
2.2
2.2.1

System Overview
System Setup

The system is built based on the schematic shown in Figure 2.1 (b). To configure
the experimental setup, a fluidic chamber was first constructed by placing a
patterned PDMS layer (thickness of 1.5 mm) between glass slides (thickness of 1mm)
as a spacer. The inlet and outlet of the fluidic chamber were made through an
opening on the glass slide where tubing was connected. A laser cutter was used to
define the dimension of the fluidic channel by forming a 30 mm by 3.8 mm opening
in the PDMS layer. The fluidic chamber was mounted on a hollow acrylic stand
(shown in Figure 2.1 (b)), in which a neodymium permanent magnet was inserted to
provide a magnetic field from below. The inlet of the chamber was connected to the
fluid source while the outlet was connected to a peristaltic pump (New Era Pump
Systems, NE-9000) and drained into a waste container or a collection tube (Figure
2.2).

Figure 2.2. Experimental setup of the entire system.
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2.2.2

Device Assembly

The device consists of seven basic components: acrylic cover, acrylic stand, top
glass fluid cover, bottom glass fluid cover, fluid channel (PDMS layer) and magnet.
The assembly scheme is shown in Figure 2.3.

Figure 2.3. Exploded view drawing of the first-generation system.

Fluid channel: The fluid channel is defined by a PDMS (polydimethylsiloxane)
frame sandwiched between the two glass slides. PDMS is optically clear, chemically
inert, non-toxic, and non-flammable. Thus it is one of the most widely used materials
in microfluidics and bio-MEMS [63].
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A laser cutter (Universal Laser Systems, VLS 3.60) was used to define a
rectangular channel (30 mm by 3.8 mm) in the PDMS layer.
Fluid cover: Top and bottom fluid covers are made of laboratory glass slides. The
thickness of each glass slide is 1 mm. The inlet and outlet of the chamber were
inserted on the top cover slide by drilling two holes using a mechanical drill with a
diamond drill bit. Silicone elbow tubing was then inserted through the holes and
sealed in place using superglue.
Acrylic stand and cover: The fluidic chamber assembly is mounted on an acrylic
stand to prevent the fluidic chamber from leaking as well as to allow the placing of
a magnet at the bottom of the chamber. Both the cover and stand are made of acrylic
(Poly (methyl methacrylate)). Acrylic is a transparent thermoplastic often used as a
lightweight or shatter-resistant alternative to soda-lime glass, especially when
extreme strength is not needed. Another reason we chose acrylic glass is because it
can be patterned easily using a laser cutter.
The top fixture has a large rectangular window in the central area, which is used
for observing the detected targets. The inlet and outlet of the top fluid chamber also
go through this window. The bottom fixture has a square window for inserting a
magnet. The device assembly was fixed and tightened on the acrylic stand using four
pairs of bolts and nuts.
Permanent magnet: We used a neodymium magnet (K&J Magnetics, grade N52)
to provide magnetic force to draw magnetized entities to the glass chip surface.
Neodymium magnet is one of the most widely used type of rare-earth magnets and
is made from an alloy of neodymium, iron and boron to form the Nd2Fe14B
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tetragonal crystalline structure. The dimension of the block magnet we used is:
3/8"×3/8"×3/8", which is inserted into the opening of the bottom fixture to be
positioned beneath the fluidic chamber. The magnetic flux density of the magnet is
0.6451 Tesla on its surface.
Our characterization of the system involved detecting free FR molecules as well
as FR+ cells in the same sample fluid. We describe below the experimental
conditions and protocols we have used for this characterization and testing process.
2.3
2.3.1

Methods and Materials
Preparation of FR antibody-coupled Magnetic Beads.

To prepare the anti-FR beads, streptavidin-coated 1 µm magnetic beads (20 µL, 10
mg/mL, Sigma Aldrich) were incubated with biotinylated polyclonal antibodies against FR
(10 µL, 0.2 mg/mL, R&D Systems) in a phosphate buffered saline (PBS) solution at room
temperature for 1 hour. After incubation, the beads were washed 3 times with PBS using a
magnetic stand to remove unbound antibodies.
2.3.2

Preparation of KB Cells and FR.

FR+ KB cells, obtained from American Type Culture Collection, were cultured in folic
acid depleted RPMI 1640 medium (Gibco, USA) with 10% fetal bovine serum (FBS).
Before the spiking process, KB cells were harvested using Trypsin-EDTA (Invitrogen) and
re-suspended in culture medium. Cell concentration was measured by taking 5 samples
(each with a volume of 3 µL) and manually counting the cell number to obtain an average.
The suspensions were subsequently spiked into medium or blood to achieve the desired
concentrations.
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Recombinant human folate receptor (FR) was purchased from R&D systems and stored

at -20℃ with a concentration of 100 μg/mL in PBS. FR was diluted and added into medium
or blood to desired concentrations for characterization and detection experiments.
2.3.3

Blood Samples for KB and FR Spiking Experiments.

Blood was collected from healthy volunteers under an approved IRB protocol. Deidentified blood samples were drawn and collected in BD vacutainer tubes with additives

of sodium polyanethole sulfonate (SPS). Blood samples were kept at 4 C immediately
after collection until the spiking process. Blood samples were used within 12 hours after
being collected (usually within 4 hours) to ensure the viability of blood cells.
2.3.4

Ascites Sample for Dual-target Detection.

Ascites from a recurrent ovarian cancer patient with stage IIIC high grade serous primary
peritoneal carcinomatosis was collected at the Indiana University Hospital and kept at -20
C until experimentation. Prior to processing the ascites fluid was thawed and filtered (pore
size: 100 µm) to remove large impurities in the fluid.
2.3.5

Fluorescent Staining for Free FR and FR+ Cell Quantification.

Earlier studies have shown that fluorescein isothiocyanate-conjugated folate, i.e. folateFITC, is effective in imaging FR+ malignant tumors with very low background in FR-

malignant or benign lesions [64]. In this study, 10 μM of folate-FITC was used to stain
both free FR molecules and FR+ cells captured by the anti-FR beads. Free FR molecules
were sandwiched between the folate-FITC and the anti-FR on the beads. While detecting
cells, folate-FITC not only made it easier to identify whole cells on the glass surface but
also served as an independent check for FR positivity (in addition to the antibody mediated
bead binding which can be observed in bright field). For characterization experiments
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performed in media, folate-FITC was incubated with captured targets under static
conditions at room temperature for 1 hour. For analysis of bodily fluids, 34 nM of CD45
monoclonal antibodies conjugated with phycoerythrin (anti-CD45-PE, Abcam, USA), and

0.18 μ M of 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, USA) were also
introduced in addition to folate-FITC to recognize white blood cells and to identify
nucleated cells.
For experiments that involved blood, red blood cell (RBC) lysis buffer (G-Biosciences,
USA) was introduced into the chamber after the cell capturing process, and incubated for
5 minutes to remove residual RBCs. Cells captured on the glass surface were then fixed
using 4% paraformaldehyde (PFA, Santa Cruz Biotechnology, USA) in PBS. Folate-FITC,
anti-CD45-PE and DAPI were subsequently introduced into the fluid chamber and
incubated under static conditions at room temperature for 1 hour. After incubation, the
fluidic chamber was washed with PBS at a flow rate of 4 mL/min for 30 seconds, and was
subjected to fluorescence microscopy for enumeration of the cancer cells as well as
quantification of FR concentration.
2.4
2.4.1

Results and Discussion
Modeling and Simulation

To assess the system functionality in capturing magnetic particles we generated a
computer-based numerical simulation using COMSOL Multiphysics 4.3a modeling
software. COMSOL Multiphysics is a finite element analysis, solver and simulation
software package that is especially useful for modeling systems involving multiple
domains.
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We first modelled the magnetic and fluidic fields inside the fluidic chamber and
defined the primary forces acting on an entity inside the chamber. Then a particle
trajectory module (PTM) was applied to obtain the trajectories of 300 beads and 30
cell-beads complexes. Here 30 is a number close to the number of CTC present in
patient blood, while 300 was the maximum number of particles that our computer
was able to handle within its computational capacity. This number however was
sufficient to obtain an intuition on how the particles behave under the influence of
flow and magnetic force.
Magnetic field modeling. We first simulated the magnetic field generated by the
permanent magnet placed underneath the fluidic chamber. COMSOL provides a
module, “Magnetic Fields, No Currents”, to simulate the magnetic field associated
with a permanent magnet. This module requires users to input three groups of
parameters: 1. magnetic properties including vacuum permeability (
permeability (

), remanent flux density (

), relative

) and magnet dimensions; 2. boundary

conditions and initial values; 3. a constitutive relationship (

=

+

). Then

the software solves the partial differential equations using finite element methods to
obtain the numerical magnetic field information such as flux density with
corresponding spatial coordinates.
Figure 2.4 shows the distribution of the flux density. Simulated results indicate
that in the vertical direction the magnitude of the magnetic flux density decreases as
the distance from the magnet surface increases; while in horizontal direction the
maximum magnitude occurs at both edges of the magnet. Once we have the
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magnetic flux density, we can calculate the magnetic force acting on magnetized
particles passing through the chamber.
(a)

(b)

Figure 2.4. (a) The colormap of magnetic flux density magnitude. (b) The distribution of
flux density magnitudes. The lateral (x-coordinate) range it starts from the left edge of the
magnet to end at the right edge. Solid lines with different colors represent flux density
magnitudes (|B|) at different distances from the magnet surface.

Fluid field modeling. The fluid field was simulated using another COMSOL
module. This begins with calculating the Reynolds number to determine the flow
type. According to the fluidic channel dimensions (length, 25.4 mm × width, 3.8
mm × height, 1.5 mm) and the flow properties, the Reynolds number was calculated

to be R =18.87. Therefore, the flow was considered to be laminar (R < 2100). After
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that we input fluid-related properties including: inlet flow rate, dynamic viscosity,
fluid density as well as channel dimensions. Then the software solves the partial
differential equations using finite element methods to obtain the numerical fluid
field information such as velocity spatial distributions. This information can be used
to solve for the fluid force acting on all particles passing through the chamber. Figure
2.5 indicates the simulated results of the fluid field inside the single-layer fluid
chamber. Figure 2.5 (a) shows a color map representing the velocity magnitude at a
flow rate of 3 mL/min, and Figure 2.5 (b) is a magnified region of the fluid field
where black arrows denote the direction and magnitude of fluid velocity with the
corresponding spatial coordinates. This means that flow velocity is maximum in the
center of the channel while approaching zero near the walls.

Figure 2.5. Simulated results of the fluid flow field. (a) The velocity field inside the
chamber; (b) Zoomed-in region with arrows denoting both direction and magnitude. The
units of flow velocity and coordinate are m/s and m, respectively.
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Multi-domain modelling. The forces acting on a particle (either a single bead or a
cell-bead complex) in the chamber include the magnetic force, the drag force induced by
the flow, gravity, and the buoyant force. To simplify the simulation, we assumed that the
internal magnetization between the particles, the influence of the particles on fluidic field,
and the coupling between fluidic and magnetic fields were negligible. We further assumed
that the magnitude of the magnetic force acting on each cell-bead complex is directly
proportional to the number of the beads bound to that particular cell, since this force acts
directly on the beads not on the cells themselves. The magnetic force F , which is one of
the dominant forces in the system, can be estimated by [65, 66]:

=

∇

∙

where V is the volume of the particle (2.4×10

(2.1)
m for a KB cell and 5.2×10

m

for a magnetic bead); χ =2.7 the effective volumetric magnetic susceptibility; μ the
vacuum permeability; and B the magnetic flux density, which is shown in Figure 2.4 (a). N
is the number of beads attached to a cell and is simply equal to 1 for the case of a free bead.
The resulting magnetic force applied on a bead at the detection surface (~1.1 mm from
the magnet top surface) in the chamber is shown in Figure 2.6. Blue solid line represents
lateral magnetic force whereas green dashed line represents the vertical magnetic force. It

can be inferred from the simulation that the magnetic force tends to pull down (ydirection force) the magnetized particles (bead and cell-bead complex) passing
through the chamber and accumulate (x-direction force) them near the two edges
areas.
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Figure 2.6. The corresponding magnetic force induced on a single bead on the detection
surface. The blue solid line shows the force in X (lateral) direction while the green
dashed line indicates the force in Y (vertical) direction.
In order to evaluate the force exerted on a cell that is attached to a plurality of beads, we
first determined the number of beads binding to a single cell. We performed an experiment
where, 500 KB cells were incubated with 20 µL of anti-FR beads for 1 hour. Following
that, 50 bead-bound cells were randomly selected. The number of beads bound with each
cell was counted using bright field microscopy and plotted in Figure 2.7. The average
number of beads per single cell was 80 with a minimum of 10 and maximum of 216.
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Figure 2.7. Histogram of number of beads per KB cell.
In our simulations we only considered the lower end of this range where N=10 beads/cell
to account for a conservative scenario: if a cell with the minimum number of beads can be
captured, then cells with more beads should also be captured under the same conditions.
The more complex scenario of different number of beads binding to a single cell will be
discussed and analyzed in Chapter 3 where efforts will be focused on elimination of white
blood cells (WBCs) that are non-specifically tagged with magnetic beads.
To perform the simulation, several forces (e.g. fluid drag force, magnetic force, gravity,
etc.) acting on particles are combined into the Newton second law. The fluid drag force F ,
the other dominant force, acting on a cell-beads complex is given by [65, 66]:
=6

−

where η is the fluid dynamic viscosity (10 kg m

(2.2)
s

); r the radius of particle (0.5 µm

for a single bead and 8.3 µm for a complex); U the velocity of fluid; V the velocity of
particle.
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The buoyant force F can be expressed by:
F = −ρgV

where ρ is the density of the fluid (1000 kg m
the volume of the particle (2.4×10

(2.3)

), g is the gravitational acceleration, V is

m for a cell-beads complex and 5.2×10

m for

a single bead).
F is the weight of the particle:
F =m g

.

(2.4)

The buoyant force can be expressed by:

=−

.

(2.5)

Newton’s second law yields:
=

+

+

+

(2.6)

where V is the velocity of the particle, and m is the mass of the particle, which could
be either a single free bead or a bead-cell complex. The average mass of a dry KB cell,
which is approximately 30% of the original mass, was measured to be 760 pg using a
cantilever-based resonator [67]. Hence the mass of a single ‘wet’ cell was taken as 2533
pg, which is in agreement with a previous study [68]. The mass of a single magnetic bead
with 1 µm diameter is around 1 pg. Thus the mass of a cell bound with N beads is 2533+N
pg.
Once the finite element simulation provided the velocity and displacement information
for beads and cell-beads complexes inside the fluidic chamber, we calculated their
trajectories and final locations on the chip surface. This relatively simple computational
model only accounts for a particle’s trace until it reaches the chip surface (not what happens
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thereafter e.g. bouncing off or sliding on the chip surface), yet it helps understand the
interplay between the magnetic and fluidic forces and suggests optimal operational
conditions including flow rate.
Simulation-based analysis. Flow rate is critical to cell detection yield, since it
determines how easily the magnetically-tagged cells escape from a given magnetic field.
We primarily studied the effect of flow rate on the trajectory of cells within the fluidic
chamber when they are bound with 10 magnetic beads. We simulated a scenario where 300
cells, each bound with 10 beads, flow though the fluidic chamber under the influence of a
high volumetric flow rate that varies from 1 to 6 mL/min.
Figure 2.8 (a) shows the simulation of the final distribution of 300 superparamagnetic
beads on the detection surface at a flow rate of 3 mL/min. Also shown are micrographs
taken from different locations on the chip surface after an experiment performed under the
same conditions (only the number of beads used in the simulation was deliberately kept
small to reduce computation time). The two results are in good agreement in terms of
describing beads’ distribution. Figure 2.8 (b) shows the simulation results where 30 KB
cell-bead complexes (blue dots) along with 300 free beads (red dots) were introduced into
the chamber under various flow rates. The capture rate of bead-bound KB cells was
calculated accordingly by dividing the number of cells arriving glass surface to the total
number of cells introduced and was plotted against the flow rate in Figure 2.8 (c). This
figure shows that when flow rate is as high as 4 mL/min, the system starts to lose cells. On
the other hand, when the flow rate is too low (< 2mL/min), even though theoretically the
cell recovery rate should be high, we observed that the beads tend to accumulate in small
areas, resulting in practical difficulties in imaging and discriminating cells. Hence it was
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determined that the optimized balance between throughput and cell recovery rate can be
achieved at a flow rate of 3 mL/min.

Figure 2.8. (a) Simulated distribution of beads under a 3mL/min flow rate; as well as
experimental micrographs from 5 locations on the chip; (b) Simulated distributions of
beads (red dots) and bead-bound-KB cells (blue dots) under flow rates of 1, 2, 3 and 4
mL/min; (c) Simulated capture rate of bead-bound KB cells with various flow rates (each
cell was assumed to have 10 beads attached).

39

Figure 2.8. Continued
After system design and fabrication was completed, the system was characterized
experimentally by spiking known number of targets into cell culture media and observing
the amount of targets detected. We first describe the characterization of the system for
detection of molecular markers only. We then follow with the characterization for
concurrent detection of both cellular and molecular targets.
2.4.2

System Characterization for Molecular Detection

We first characterized the system for detection of molecular markers only by detecting
known concentrations of FR (molecular mass: 25.4 kDa) added into 1 mL of culture media.
The anti-FR beads were incubated with the samples at room temperature for 1 hour to
capture the free FR. The mixture was then flowed through the detection chamber at a flow
rate of 3 mL/min, and the magnetic beads were pulled down and held on the detection
surface by the magnetic field. Afterwards, the chamber was rinsed with PBS to wash away
those unbound FR molecules and impurities. The accumulated beads were subsequently
incubated with folate-FITC for 1 hour at room temperature to stain the FR captured on the
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beads for fluorescent analysis. Figure 2.9 shows the fluorescent and corresponding bright
field micrographs of the beads captured on the detection surface with 3 different FR
concentrations, 100 nM, 1 nM and 0 nM. The intensity of the fluorescent signal emitted
from the beads increases with the FR concentration. The bright-field image provides
information of the existence and distribution of beads on chamber surface.
(a.1)

(a.2)

(b.1)

(b.2)

(c.1)

(c.2)

Figure 2.9. Fluorescent and bright images collected from samples with different FR
concentrations. Image pairs a, b and c were captured from samples with FR
concentrations of 100 nM, 1 nM and 0 nM, respectively. All fluorescent images were
equally enhanced for display.
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Algorithm for calculating effective fluorescence. To study the relationship between the
input (FR concentration) and the output (fluorescence) signals, we calculated the total
fluorescence intensity in an observation window and subtracted the background intensity
observed in a bead-free area in the same window. This fluorescence intensity was then
normalized by the intensity of the reversed bright field image, which represents the number
of the beads on the detection surface. The resulting signal, called the “B-ratio” (which
stands for “brightness ratio”), is a measure of the fluorescence signal per bead and can be
used to establish a detection curve.
Figure 2.10 shows the flow chart of B-ratio calculation. Fluorescent and bright field
images are taken from the same area. Fluorescent image is first split into three channels
with respect to red, green and blue colors, and then red and blue channels are filtered out.
The green image is converted into grayscale image; a median filter (size: 110×110) is used
to extract the background of the image. The total fluorescent intensity is then calculated
after subtracting the background. For a bright field image, it is first converted to grayscale
image and the intensity is reversed. Then the total bright-field intensity is calculated. The
B-ratio is obtained by normalizing the total fluorescent intensity with respect to the total
bright-field intensity.
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Figure 2.10. Flow chart of B-ratio calculation.
To examine whether the B-ratio is significantly dependent on bead densities (i.e. number
of beads over a given surface area), two pairs of images with different number of beads
were selected for the test. As shown in Figure 2.11, under the same FR concentration (100
nM), two pairs of images were collected from different regions of the detection surface.
The total fluorescent intensity calculated from Figure 2.11 (a.2) is 51.3% higher than that
calculated from Figure 2.11 (b.2). However, the difference in B-ratio in between the 2 pairs
of images is only 1.4%. Therefore, we conclude that B-ratio is a better output metric than
raw fluorescence intensity for calibrating the input signal, i.e. the FR concentration.
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(a.1)

(a.2)

(b.1)

(b.2)

Figure 2.11. Two pairs of bright field and fluorescent images obtained from different
locations on the detection surface. There is an obvious difference in bead distribution
density between (a) and (b). The B-ratios of the two pairs, however, are very close to
each other, which indicates the robustness of this algorithm in computing fluorescent
intensity per bead.
B-ratio vs. molecule concentration. We measured the B-ratio obtained from 8 various FR
concentrations in medium from 0 to 200 nM and plotted them in Figure 2.12. For each
measurement 3 images were acquired at different locations of the glass surface. Performing
a least squares Langmuir isotherm fit to the experimental data revealed:
B =

.

.

⁄

+ 0.08504

(2.7)

where B is the B-ratio and C is the FR concentration; 0.08504 is the bias which could
result from the non-specific binding between folate-FITC and anti-FR beads and/or the
intrinsic fluorescent background of the magnetic beads. The dissociation constant K d
between anti-FR and FR was found to be around 1.055 nM, which is in agreement with
previous reports [69, 70].
From Figure 2.12 the dynamic range of this system for detecting FR is from 10 pM to
100 nM. The sensitivity (B /C ) at FR concentration=Kd is 0.031 (nM-1). We were able to
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detect concentrations as low as 10 pM (with a 3-standard deviation difference from the
background). Although we were also able to measure lower signals at 1 pM, such signals
did not differ significantly from that of 10 pM. Clinical research shows that for ovarian
cancer patients the level of circulating FR can vary from 70 pM to 2 nM [46, 62, 71], and
thus our system is capable of detecting FR in cancer patient blood, which was further
validated by detecting FR spiked into human blood and comparing the result with that
obtained using an established method (e.g. ELISA).

Figure 2.12. Variation of fluorescence with FR concentrations from 1pM to 200 nM.
Error bars represent standard deviations from 3 measurements. Green horizontal line
represents experimental background (Br when FR=0). Gray curve is the Langmuir
isotherm fit based on Equation (2.7).
2.4.3

Characterization of the System by Detecting FR-positive Cells in the Presence of
Free FR

We next characterized the system for simultaneous detection of both cellular and
molecular targets. Around 100 KB cells and FR molecules with concentrations between 1
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pM and 100 nM were spiked in cell culture medium with a volume of 1 mL. The mixture
was then incubated with 20 μL (40 μg) of anti-FR beads for 1 h at room temperature before
flowing through the fluidic device for detection. Following that, the fluidic chamber was
subjected to folate−FITC staining and fluorescent microscopy to quantify the two targets
(cells and molecules) detected on the glass surface. To eliminate the influence of the
fluorescence signal coming from the cells on free FR quantification, the images of cells
were deliberately removed from both fluorescent and bright field images before calculating
the B-ratio (Figure 2.13).

Figure 2.13. Bright-field (a.1, b.1) and fluorescent (a.2, b.2) images obtained from the
same detection surface. In images b.1 and b.2 cells were deliberately removed for B-ratio
calculation. Image b.1 is a reverse bright field image in grayscale. White arrows point to
the locations of the captured cells.

The detection yields of the KB cells and the measured FR concentrations are plotted

against the concentration of free FR spiked in medium in Figure 2.14. We observed a
monotonic relationship between spiked and measured free FR concentrations. The free FR
concentration was estimated by comparing the measured B-ratio to the Langmuir isotherm
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fit described by Equation (2.7). Therefore, the systematic accuracy of the estimated
concentration is limited by how well the fit represents the calibration data with respect to
how much the data varies in a specific concentration region. For example, for
concentrations between 10 and 100 pM, as well as above 10 nM, the slope of the fit is
relatively small, and hence, errors in B-ratio could result in larger errors in the estimated
concentration. The difference between the Langmuir fit and the actual data can also lead to
overestimation of the concentrations at the lower end of the dynamic range. In Figure 2.14
the cell detection yield remains above 90% when the FR concentrations were below 10 pM.
However, the detection yield starts to decrease with increasing FR concentration above 10
pM. We attribute this to a competition effect between the KB cells and the free FR
molecules, whose quantity and mobility is higher than that of the cells. A high level of free
FR therefore masks the beads’ binding sites and lowers the number of FR+ cells captured
by the beads (on the other hand, the presence of cells does not significantly hamper the
capturing of molecules). Therefore, the plot in Figure 2.14 serves as a calibration curve to
estimate the original number of cells present in a sample fluid based on the number of cells
captured on the chip surface and the measured FR concentration.
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Figure 2.14. The detection yield of KB cells and the measured FR concentration plotted
against spiked FR concentration. Blue circles represent the detection yield and error bar is
one standard deviation from 3 measurements; while green squares represent the measured
FR concentration.
Besides concurrent detection of the two targets and quantifying them using fluorescent
labeling, we also verified that the fluorescent signal coming from a FR+ cell is primarily
due to the FR on the cell itself by imaging a KB cell that is not exposed to any beads (Figure
2.15).

Figure 2.15. Fluorescent images of KB cells with and without free FR. The left image is
KB cells with zero FR but beads; the central one is KB cells with 1 nM of free FR and
beads; the right one is KB cells without FR or beads.
We also performed a negative control experiment wherein we used the same procedures
in KB cell detection to attempt capturing 4T1 cell line (Life Technologies) that is known
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to be FR-negative [72]. Only 1.4% of 4T1 cells were found on the detection surface. This
experiment result indicate that anti-FR does not significantly target surface markers other
than FR.
2.4.4

Concurrent Detection of Molecules and Cells Spiked into Blood Samples

To study the potential of the system in clinical applications, FR and KB cells were spiked
into blood samples collected from a healthy donor. 500 µL of unprocessed whole blood
was first diluted with PBS solution to 2 mL. Around 100 KB cells were spiked into the
diluted blood sample and meanwhile free FR were also added to make the final FR
concentration 200 pM. The mixture was incubated with 20 µL (40 µg) anti-FR beads at 4
C for 90 mins. Each sample was then passed through the fluidic chamber (under the

influence of the magnetic field) at a flow rate of 3.0 mL/min, which was followed by
washing with 3 mL of PBS solution. The sample was subjected to fluorescence microscopy.
We identified KB cells based on a combination of factors including the size (10-30 µm),
shape (close to circular) of the observed cells and their fluorescent emissions, wherein a
Folate-FITC(+), anti-CD45-PE(-), and DAPI(+) cell was scored as a positive result. Figure
2.16 shows the fluorescent images of 3 KB cells and a leukocyte, as well as FR-beads
captured in the chamber.
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Figure 2.16. Fluorescent micrographs of cells detected from KB spiked blood. (a) KB
cells stained by folate-FITC; (b) Leukocytes stained by antiCD45-PE; (c) Cell nuclei
stained by DAPI; (d) A merged image of (a)-(c).
The FR level of the blood was measured to be 244 pM, which is slightly higher than the
FR concentration we spiked in (200 pM). This could be attributed to the intrinsic FR
present in the healthy blood. The number of KB cells detected on the chip was counted to
be 62. Based on the measured FR level and the KB detection yield in Figure 2.14, the
estimated total number of KB cells present in blood was calculated to be 98, which is in
agreement with the number we spiked in (100). The set of experiments performed thus far
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demonstrated the system’s capability to simultaneously detect rare cells and protein
biomarkers from human blood. We next investigated the system’s potential to detect target
entities in bodily fluids other than blood.
2.4.5

Concurrent Detection of Free FR and FR+ Tumor Cells in Ascitic Fluid

The system was finally challenged to detect FR and FR+ cells present in bodily fluids
obtained from a cancer patient. For this purpose, ascites was obtained from a patient with
stage IIIC ovarian cancer (high grade serous primary peritoneal carcinomatosis). Ascites is
the accumulation of fluid in the abdominal cavity that occurs in a number of clinical
conditions. In the case of ovarian cancer, the “ascitic fluid” or simply “ascites” normally
contains protein biomarkers as well as tumor cells. Filtered malignant ascites (1 mL) was
first diluted to 4 mL with PBS buffer. Following the protocol described previously but
without adding any free FR or KB cells, intrinsic FR+ cells and free FR were captured and
fluorescently stained for identification and quantification. Once again, only those cells
showing folate-FITC+, DAPI+ and anti-CD45- were scored (those cells that appeared
triple-positive, i.e. folate-FITC+, DAPI+ and CD45+, were excluded from scoring). We
captured 43 FR+ cells and measured 940 pM of FR from the diluted sample (i.e., 3.8 nM
FR for the original sample, Figure 2.17).

Figure 2.17. Example of fluorescent and reversed bright images from ascites sample.
Note: the fluorescent image, i.e. (a. FL), was enhanced for display.
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Using the free FR concentration along with the calibration data in Figure 2.14, the
original number of FR+ cells present in the 1 mL of ascites can be estimated to be around
101.
To verify the results obtained using our system, FR concentration and number of FR+
cells present in the same ascites sample were also determined using ELISA and flow
cytometry respectively. An ELISA kit for FR measurement was purchased from R&D
system (Human FLOR1 Quantikine ELISA Kit, DFLR10). Following the protocols
provided by the vendor, various concentrations of standard folate receptor included in the
kit were first used to generate a reference curve. Ascites samples (200 µL) were diluted by
100-fold and then 50 µL of diluted sample was measured based on the reference curve. The
resulting FR concentration of the diluted ascites was measured to be 44.7 pM, which yields
an FR concentration of 4.5 nM in the original ascites. This value is in reasonable agreement
with the FR concentration measured by our system (3.8 nM).
To detect FR+ cells in the ascites sample using flow cytometry, a total volume of 1 mL
of ascites was first diluted to 2 mL with PBS buffer and separated into 2 tubes. Following
that 10 µM of folate-FITC was introduced and incubated for 30 minutes to stain FR+ cells.
All mixtures were then centrifuged and the supernatants were aspirated. The cell pellets
were suspended in 250 µL of PBS buffer before introducing into a flow cytometer (BD
Biosciences, ACCURI C6). The total number of folate-FITC+ cells was 167, in comparison
with what we estimated using our system (101 cells). The difference could be attributed to
the following reasons: (1) In our system we observed and excluded some triple-positive
cells (folate-FITC+, DAPI+, and CD45+), which would normally be counted by a flow
cytometer that simply scores all FITC+ cells. (2) The calibration curve in Figure 2.14 was
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obtained for a specific type of cell that has a high expression of FR and hence can result in
underestimating the number of other cells if they have a weaker expression of FR. (3) Since
the concentration of target cells sought is relatively small (only some 100 within some mL),
it is possible that two separate volumes, even if they come from the same original sample,
may not contain exactly the same number of cells. Given these possibilities, the difference
in the number of cells estimated in the two independent experiments is reasonable.
2.5

Discussion

In Chapter 2, a relatively simple immunomagnetic system capable of simultaneous
detecting free molecules and whole cells was presented. The concept was demonstrated by
applying the system to detection of free FR molecules as well as FR+ cells. The optimal
flow rate was found to be 3 mL/min based on a computational model, and the system was
characterized using this flow rate by detecting both molecular and cellular targets spiked
in cell culture medium. The dynamic range of FR detection was found to be between 10
pM and 100 nM; whereas the detection yield of KB cells was found to be dependent on the
FR concentration due to a competition effect between both targets. Therefore, a calibration
curve was obtained to use the number of cells captured on the chip surface along with the
measured FR concentration to estimate the number of cells in the original sample fluid. We
also showed the concurrent measurement of FR and KB cells spiked in healthy blood,
which demonstrates the potential of this system in clinical applications. Finally, we applied
this system to the analysis of a bodily fluid obtained from a cancer patient, where we
detected free FR as well as FR+ cells endogenously present in the ascites fluid of an ovarian
cancer patient. The results were further confirmed with commercial tools including flow
cytometry and ELISA.
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The concept, on which this system is built, is generic and versatile, and hence the same
principles could be applied to detection of a wide range of cells and molecular biomarkers
present in various bodily fluids. Adjustments in antibody, bead type (magnetic content,
dimension) as well as experiment conditions (e.g. temperature, incubation time, flow rate)
enable this system to capture different cell and molecule targets.
The system however places an inherent limit on the number of beads that can be used.
For many applications, such as rare cell detection, the number of beads needs to be
maximized in order to capture as many of the target entities as possible. However, since
both whole cells and free beads are collected on the same surface, a significant increase in
number of beads introduces the danger of covering up the cells and making their
recognition challenging and sometimes impossible. Hence, due to the lack of spatial
separation beads from cells, this system is limited to relatively small sample volumes (and
hence relatively low number of beads). Therefore, an improved system, which has the
capability to process large number of beads (2-3 times of the beads used in first generation
system) is needed. Such a system can separate cell-bead complex from free beads and even
retrieve captured cells for downstream analysis. This desired system will be presented in
Chapter 3.
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CHAPTER 3. SECOND-GENERATION SYSTEM FOR CTC DETECTION

3.1

Introduction

In this chapter, the second-generation system is presented as the improved version of the
first-generation system. Similar to first generation system, second generation system
employs immunomagnetic separation and parallel flow to capture targets from sample fluid.
However, in order to overcome the inability of the first-generation system in separating
cells from smaller entities (i.e. free beads), a micro-aperture chip composed of an array of
micro-apertures (8 µm diameter) is incorporated as the size filter between the top and the
bottom chambers (Figure 3.1 (a)) to sort out free beads into the lower chamber. Even
though the ultimate goal of the thesis is to achieve concurrent detection of both cellular and
molecular targets, Chapter 3 mainly focuses on the more challenging aspect of cell
detection. Therefore, in this chapter the second-generation system is developed and applied
for on-chip isolation and detection of CTCs from patient samples.
As mentioned in Introduction, CTCs are rare cells present in the blood of cancer patients.
They are shed from both primary and metastatic tumors and are believed to play a key role
in cancer progression (e.g. indicators of metastatic disease and recurrence after surgery)
[73-77]. The CTC count has been reported to correlate with overall tumor burden, and
hence CTCs have been proposed as a biomarker for monitoring disease progression and
response to therapy [23, 78-80]. Another major advantage of CTCs is that they can be
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further interrogated after detection. For example, sequencing of the genome and
transcriptome could reveal mutations or quantitate gene expression. The detected cells also
have the potential to be cultured, grown and tested with different combinations of
chemotherapeutic agents for drug discovery and personalized medicine. Thus, CTC
detection is of great significance in early diagnosis of cancer, prognosis and therapy
evaluation.
The general detection strategy for the second-generation device is demonstrated in Figure
3.1 (a). The sample mixture, pre-incubated with magnetic particles functionalized with
antibodies against targets, is introduced into the top chamber using a high volumetric flow
rate. A permanent magnet (the same one used in the first-generation system) positioned
beneath the device provides the magnetic field to pull the targets bound to magnetic beads
toward the micro-aperture chip. The free beads, owing to their smaller size (~1 µm), are
drawn down to the bottom chamber through the holes. On the other hand, the target cells
bound to beads are retained on the micro-aperture chip due to their relatively larger size
(15-20 µm). The cellular targets are then subjected to fluorescent microscopy for
quantitative analysis: the cells are identified and counted on chip surface in the top chamber
(Figure 3.1 (b)).
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(b)

Figure 3.1. (a) 3D schematic graph of the micro-aperture chip system; (b) SEM image of
captured cells on chip surface.
The operation process is illustrated in Figure 3.2. Cells tagged by antibody-conjugated
magnetic beads are captured by means of an external magnetic field in the fluid device,
similar to that in the first-generation device. But unlike the first-generation system, here,
the micro-aperture chip leads to the size-based separation of the larger cell-bead complexes
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into the upper chamber with the smaller free bead complexes passing through the microaperture holes into the lower chamber (Figure 3.2(a)). Often, many free magnetic beads

still remain on the chip surface if they do not initially find an aperture to pass through.
To alleviate this problem, a secondary, smaller magnet is situated on the top of the
fluidic chamber in a stable orientation where it is attracted by the larger magnet in
the bottom. The second magnet is subjected to an oscillating horizontal motion
(Figure 3.2(b)) which perturbs the horizontal magnetic force applied on the beads
and therefore guides them to adjacent apertures. The captured cells are then analyzed
using immunofluorescence while they are still on the chip surface for identification
and enumeration (Figure 3.2(c)).

Figure 3.2. Flow of detection and enumeration of CTCs.
Although at this stage only cells (and no molecules) were targeted, this system has been
extensively characterized and examined in its capability to perform high-throughput, highpurity detection, using large number of beads and multiple antibodies for high detection
yield. Such optimization and validation constituted the first step to achieving the version
that performs concurrent detection of both cells and molecules (which is the topic of
Chapter 4). There are multiple advantages of the micro-aperture system over the single-
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layer system. Larger number of beads can be used to realize multiplex assay as well as to
increase cell detection yield. As shown in Figure 3.3, using a single-chamber prototype
(Figure 3.3 (left)), cells (KB cells) and beads could be simultaneously captured on a glass
slide. However, due to the inability to separate the larger cell-bead complexes from beads,
the ability to perform quantification was limited. Captured cells were occasionally buried
under large bead accumulations (Figure 3.3 (Left)) and could thus not be easily counted
via bright-field or fluorescence microscopy. As a result, relatively small number of beads
had to be used, which could be a limiting factor in rare cell detection where every cell is
precious and should not be missed due to scarcity of beads used. Moreover, since beads are
separated into the bottom layer, during quantitative analysis (e.g. cell enumeration)
interference from those entities is efficiently reduced, therefore visualization and imaging
could be improved, purity of the captured cells can be enhanced, and the overall versatility
of the system can be improved.
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Figure 3.3. Bright-field images on the left are for the single-chamber prototype
containing a glass slide (viewed from the top). Images on the right are for the dual
chamber system in which the micro-aperture chip surface (viewed from the top) is
presented. The micro-aperture chip contains an array of ~8 µm diameter holes that appear
dark. The top row of images corresponds to unused surfaces. The middle row shows the
results of 80 µg of magnetic beads (incubated in culture media without cells) captured
using both devices. The dark spots and roughened background for the glass chip are due
to the beads, which contrast to the clear micro-aperture chip surface. The bottom row
reveals the results of the same experiment as for the middle section but in the presence of
target cells. Cells are identified with white arrows and appear dark due to being bound to
antibody conjugated magnetic beads. The large cluster and bead-background on the glass
surface limit the ability for accurate cell quantification.
In this Chapter, breast cancer cell line MCF-7 cells were used as model of CTCs in both
numerical analysis (as opposed to the KB cells used with the first-generation device) and
the characterization experiments. The numerical model was developed using finite element
analysis to help understand the physical operation of the system as well as to find the
parameters for optimal system performance. The simulation was verified by spiking 70
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MCF-7 cells pre-labelled with magnetic beads that were conjugated with antibodies
against EpCAM (anti-EpCAM) into blood and study the relationship between the
capture yield and flow rate. Then the system was characterized by detecting MCF-7 cells
spiked into blood (from 0 to 110 cells/8 mL) to mimic analysis of blood samples obtained
from cancer patients. Since MCF-7 highly expresses epithelial cell adhesion molecule
(EpCAM), beads conjugated with anti-EpCAM (anti-EpCAM bead) are primarily used in
the characterization experiment [81]. Finally, we demonstrate the utility of the system

in detecting CTCs in blood samples collected from patients with non-small cell lung
cancer (NSCLC, N = 38) and pancreatic cancer (PANC, N = 12). In CTC detection,
a combination of different antibody beads was used in order to target multiple surface
antigens on the surfaces of CTCs present in cancer patients’ blood samples [81-83].
3.2
3.2.1

Material and Methods
Micro-aperture Chip

The micro-aperture chip that contains an array of 8 µm apertures is placed parallel
to the flow field in the chamber and serves as a size-based filter to separate whole
cells (usually larger than 10 µm) from beads (around 1 µm) that are not bound to
cells. The micro-aperture chips were produced using conventional silicon
fabrication processes. The fabrication was performed on double-side-polished,
<100> oriented intrinsic silicon wafers (4”) with a thickness of 550 µm, and the
process flow was described in Figure 3.4 [84]. Photoresist (PR) AZ9260
(MicroChemical) was first spin-coated onto the front side of the wafer following by
a soft-bake at 110C for 10 minutes. Subsequently the PR was exposed and
developed using an AZ400:DI water mixture (1:4 by volume). Deep Reactive Ion
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Etching (DRIE, STS ASE) was used to selectively etch the silicon for 50 µm to
create an array of cylindrical cavities. The PR was then removed using acetone and
a layer of low stress silicon nitride (100 nm) was deposited on both sides of the wafer
using low-pressure chemical vaper deposition (LPCVD, Protemp Horizontal
Furnaces). Once again AZ9260 was spin-coated on the wafer, only this time on both
sides, and was soft-baked. On the back side the PR was patterned to open up a
window and the nitride was dry-etched using SF6 plasma (Plasma Tech RIE 80).
Following that, the wafer was placed in a 40% potassium hydroxide (KOH) solution
at 80C for wet etching of the silicon from the back side. The process was carefully
monitored and stopped when silicon was etched till the bottom of the holes (when
light could transmit through the holes). The remaining nitride layer was stripped by
immersing the wafer into HF:DI water = 1:10. Finally, the wafer was cleaned using
piranha solution (H2SO4:H2O2 = 3:7), ethanol and DI water to remove any residuals
and particles.
At the end of the fabrication process, 8 pieces of micro-aperture chips (40 mm by
20 mm), each with a 9 mm by 3 mm porous area (50 µm thick) at the center, were
obtained from a single 4” silicon wafer. Figure 3.4 (g) and (h) show SEM images of
the porous area of a micro-aperture chip.
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Figure 3.4. (a)–(f) Fabrication process flow and (g–h) SEM images of a fabricated microaperture chip. Each aperture is 8 µm in diameter.
3.2.2

Experimental Setup

Similar methodologies and materials (section 2.2.1) were used to configure the
experimental setup. A fluidic chamber was first constructed by placing a layer of
polydimethylsiloxane (PDMS, ~2 mm-thick) on a micro-aperture chip as a spacer
and covered with a 1 mm-thick glass slide. The inlet and outlet of the fluidic chamber
were opened on the cover slide. The dimension of the fluidic channel that encloses
the porous area was defined by patterning the PDMS using a laser cutter (Universal
Laser Systems, VLS 3.60) to have a 30 mm by 3.8 mm grove. The bottom of the
micro-aperture chip was also sealed with a thin layer of PDMS coated on a
transparency film (3M PP2500). The thickness of the PDMS-transparency film
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complex was 0.1 mm. The assembled fluidic chamber was mounted on a hollow
acrylic stand (shown in Figure 3.5(b)), in which a neodymium permanent magnet
(K&J Magnetics, grade N52) could be inserted to provide a magnetic field. The inlet
of the chamber was connected to the fluidic sources while the outlet was connected
to a peristaltic pump (Ismatec ISM596B) and drained into a waste container or a
collection tube (Figure 3.5 (c)).

Figure 3.5. (a) A SEM image of a fabricated micro-aperture chip. (b) A picture of the
microfluidic chamber assembly and (c) the experimental setup.
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3.2.3

Experimental Procedures

Detecting MCF-7 cells spiked into blood. We performed an initial characterization of the
system by detecting known number of cells spiked into healthy human blood. A series of
suspensions were prepared by spiking 0 to 110 MCF-7 (breast cancer cell line) cells into 8
mL of blood collected from healthy donors under an approved IRB protocol (8 mL is the
volume of a typical blood collection tube). The spiked blood samples were first treated
with a red blood cell (RBC) lysis buffer (G-Biosciences) followed by centrifugation to
remove the supernatant. The remaining cells were re-suspended in 1.5 mL of phosphate
buffered saline (PBS, Invitrogen) and incubated with 4 μL (40 μg) of anti-EpCAM beads
at 4 °C for 1 hour. The sample was then circulated in the fluidic chamber (with the bottom
magnet in place) at a flow rate of 2 mL/min for 3 minutes, which was followed by washing
with 3 mL of PBS solution. The captured cells were fixed on the chip and subjected to
immunofluorescence analysis to identify and enumerate the MCF-7 cells.
CTC detection in blood samples of NSCLC and PANC patients. Patients with advanced
NSCLC and PANC were recruited for this study under an approved IRB protocol. Blood
samples from 38 NSCLC and 12 PANC were collected. An 8 mL blood sample from each
patient was either divided into 2 equal volumes of 4 mL s or used as a single 8 mL entity
for examination. A combination of anti-EpCAM, anti-EGFR and anti-VMT beads (1 : 1 :
1) were used with the NSCLC samples; and a combination of anti-EpCAM and anti-CEA
beads (1 : 1) were used with the PANC samples. A group of beads was functionalized with
only one type of an antibody. Multiple bead groups, each containing a different antibody
were then added into the sample mixtures for incubation. The rest of the protocol was the
same as that used in the detection of MCF-7 cells spiked into blood.
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Blood sample collection and preparation. Blood donated by healthy volunteers as well
as NSCLC and PANC patients was collected in BD Vacutainer tubes with additives of
either acid citrate dextrose (ACD) solution A or sodium polyanethol sulfonate (SPS). Blood
samples were kept at 4 °C starting immediately after collection until the detection process
which occurred within 12 hours of collection.
Preparation of magnetic beads conjugated with antibodies. Antibodies against EpCAM,
EGFR, CEA and VMT were separately conjugated to magnetic beads freshly before
detection. Biotinylated polyclonal antibodies against human EpCAM and CEA were
purchased from R&D systems. Biotinylated monoclonal antibodies against human EGFR
and VMT were purchased from Abcam. Streptavidin conjugated superparamagnetic beads
with 1 μm diameter were obtained from Sigma Aldrich. We saturated the beads (20 μL, 10
mg/mL) with excess amounts of antibodies (10 μL, 0.2 mg/mL) in PBS at room
temperature for 1 hour, followed by rinsing with PBS three times on a magnetic stand and
re-suspending in PBS.
Cell culturing and preparation of cell suspensions. The breast cancer cell line MCF-7,
obtained from American Type Culture Collection (ATCC), was cultured in Eagle's
Minimum Essential Medium (EMEM, ATCC) with 0.01 mg/mL bovine insulin (SigmaAldrich) and 10% fetal bovine serum (FBS, Gemini Bio Products). Cultured cells were
harvested using Trypsin-EDTA (Invitrogen), and were re-suspended and diluted in culture
media immediately before cell detection experiments. The original cell concentrations were
determined by placing 3 μL of the cell suspension on a glass slide to count the cells using
a bright field microscope and calculating the average from 4 measurements. The cell
suspension was then spiked into blood to achieve the desired concentrations.
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Immunofluorescence analysis. Cells captured on the micro-aperture chip surface were
first fixed using a 4% PFA solution in PBS and then labeled fluorescently while the microaperture chip was in the fluidic chamber. Anti-pan Cytokeratin monoclonal antibodies
conjugated with FITC (anti-CK-FITC, Abcam, USA), anti-CD45 monoclonal antibodies
(to rule out white blood cells) conjugated with phycoerythrin (anti-CD45-PE, Abcam,
USA), and DAPI to verify nucleated cells (Sigma-Aldrich, USA) were introduced into the
chamber at the same time and incubated for 1 hour at room temperature to label the cells.
After washing away the unbound antibody-dye with 3 mL of PBS, the micro-aperture chip
was inspected while still in the fluidic chamber using a fluorescent microscope (ECLIPSE
80i, Nikon) with a Fiber illuminator (C-HGFI, Nikon).
3.3
3.3.1

CTC Detection
Modeling and Simulation

The micro-aperture chip system was modeled and simulated following the same
principles and procedures described in Chapter 2. In this section, we first investigated the
system’s ability to capture cells. We primarily studied the effects of flow rate on the
trajectory of cells within the fluidic chamber when they are bound by various numbers of
magnetic beads. Then we investigated the lateral movement of the free beads on the microaperture chip's surface resulting from the motion of an additional magnet situated on the
top of the fluidic chamber.
Detection mode. We simulated a scenario where certain number of MCF-7 cells, each
bound with a given number of beads (1-10 beads/cell), flow though the fluidic chamber
under the influence of a high volumetric flow rate that varies from 1 to 5 mL/min. The
dimensions of the fluidic chamber used in the simulation were (L×W×D = 30×3.8×2.0 mm),
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which are defined by a PDMS spacer in the fluidic chamber. The experimental parameters
yield a Reynold's number of 4.58 indicating that the flow in the chamber is in general
laminar. To simplify our simulation, we assumed that the porous structure does not have
any significant effects on the bulk fluidic field. Meanwhile we keep all the assumptions
mentioned in Chapter 2.
The forces acting on a cell–beads complex in the chamber included the magnetic force,
the drag force induced by the flow, gravity, and the buoyant force. We further assumed that
the magnitude of the magnetic force acting on each cell–bead complex is proportional to
the number of the beads bound to that particular cell, since this force acts directly on the
beads, and not on the cells themselves. The magnetic force

, which is one of the

dominant forces in the system, can be expressed by [65, 66]:
=N

∇( ∙ )

where N is the number of beads attached to a cell;

(3.1)
is the volume of a single bead (5.24

× 10−19 m3); χ the effective volumetric magnetic susceptibility (2.7 unitless);

the

vacuum permeability; and the magnetic flux density (produced by the N52 magnet), which
is shown in Figure 3.6 (a). The resulting magnetic force applied on a single bead at the
detection surface of the micro-aperture chip is shown in Figure 3.6 (b), where the green
dashed line represents the magnitude of the vertical force (negative indicates a downward
force) while the blue solid line represents the magnitude of the longitudinal force (positive
indicates a force to the right). According to the results shown in both Figure 3.6 (a) and (b),
magnetic particles tend to accumulate above two edges of the magnet because the lateral
(x-direction) magnetic force concentrates particles in the two edge areas.
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The fluid drag force F , the other dominant force, acting on a cell–bead complex is given
by [65, 66]:
F = 6πηr (U − V )

(3.2)

where η is the fluid dynamic viscosity (2.5×10−3 kg m−1×s for processed blood sample); rp
the radius of particle (5 μm for a MCF-7 cell); U the velocity of fluid; and V the velocity
of particle.
The gravitational force applied on a complex is:
F =m g

(3.3)

where g is the gravitational acceleration and mp is the mass of the cell–beads complex. The
average mass of a dry MCF-7 cell, which is approximately 30% of the original mass, was
measured to be 0.43 ng using a cantilever-based resonator [67].
The mass of a single magnetic bead with 1 μm diameter is around 1 pg. Hence the mass of
a single cell bound with N beads is 1433 + N pg.
The buoyant force can be expressed by:
F = −gρ

(3.4)

where ρ is the density of the fluid (~1000 kg m−3) and V is the volume of a cell–beads
complex, which is approximately 5.24 × 10−16 m3.
The contribution of gravitation (~14 pN) and buoyancy (~5 pN) are relatively small, yet
their inclusion in the model is straightforward. Applying the Newton's second law yields:
=

+

+

+

(3.5)
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Figure 3.6. (a) The simulated magnetic flux density pattern of a N52 magnet and (b) the
corresponding magnetic force applied on a single bead in the fluidic chamber. The green
dashed line shows the magnitude of the vertical force while the blue solid line indicates
the magnitude of the horizontal force. (c) Illustration of simulated trajectories of cell–
beads complexes in the fluidic chamber.
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We applied the particle tracing module in COMSOL to solve for the velocity and the
displacement of the cell–beads complexes (as demonstrated in Figure 3.6 (c)). Based on
the obtained trajectories the percentage of the cell–beads complexes reaching the microaperture chip surface was estimated.
To accomplish this, we first experimentally determined N (Equation (3.1)), and used it
in our computational model to study the effect of flow rate on the rate with which the cells
encounter the surface of the chip.
To understand the extent of the specificity in the binding of beads, a study was carried
out on how anti-EpCAM beads bind to MCF-7 cells as well as non-specifically to WBCs.
This characterization is important since WBCs are the main contaminants in this assay and
their presence on the chip surface hinders both the enumeration process, as well as the
purity of the CTCs acquired for downstream analysis. Around 200 MCF-7 cells, as well as
white blood cells (WBCs) isolated from 4 mL of healthy blood were first suspended in two
separate tubes, added to 1.5 mL of PBS buffer, and incubated with 4μL (40μg) of antiEpCAM beads at 4°C for over 1 hour. The cells were aspirated using a micro-pipette,
transferred onto a glass slide and the beads on their surfaces were counted using a brightfield microscope with high magnification. The number of beads bound to each MCF-7 cells
ranged from 3 to 63 with an average of 16.8 beads per cell, while majority of the WBCs
(>99%) did not bind to any bead at all. For those WBCs that did bind to beads, the number
of beads found on each WBC ranged from 1 to 19 with a mean of 2.3 beads per cell. The
distribution of number of beads on each cell group is shown in Figure 3.7 (a) (the relative
frequency for WBCs was calculated only for those that bound with beads). The histograms
of MCF-7 and WBCs overlapped mainly when N<10. Figure 3.7 (a) also shows that around
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90% of the MCF-7 bound to at least 7 beads, while around 90% of the bead-bound WBCs
had 1 to 4 beads.

Figure 3.7. (a) Histograms in semi log-scale showing distribution of number of antiEpCAM beads bound on MCF-7 cells and white blood cells (WBCs). All MCF-7 cells
bound to at least 3 beads, while over 99% of WBCs did not bind to any beads. The
relative frequency was calculated only for cells that bound to beads. (b) Simulated chip
surface encounter rate of 100 cell–beads complexes vs. the flow rate. (c) Capture yield of
pre-labeled MCF-7 cells (with beads) spiked in blood vs. the flow rate. Error bars
indicate standard deviations from 3 measurements.
Using this information, we simulated the trajectories of bead-bound cells under the
influence of flow rates ranging from 1 to 5 mL/min. Figure 3.7 (b) shows the effect of flow
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rate on discriminating cells based on the number of beads they are bound to. According to
Figure 3.7 (b), the optimal flow rate of our system is about 2 mL min -1 since at this flow
rate, cells bound with 7 or more beads (90% of cancer cells) encounter the chip surface
with a probability of 96% or greater. At the same time, cells that are bound to fewer than
4 beads (90% of bead-bound WBCs) encounter the chip surface with a much lower
probability. This relatively simple computational model only accounts for a cell's motion
until it encounters the chip surface and not what happens afterwards (e.g. bouncing off,
colliding with other particles, or moving on the chip surface etc.). However, it effectively
confirms the basic relationship between the flow rate and the number of beads and suggests
that an optimal choice of a flow rate could help reduce capturing unintended cells that are
bound to small number of beads non-specifically without significantly hampering the
specific capturing of cancer cells, and that too low a flow rate (e.g.<2 mL/min) could
increase the capture of unintended cells without a significant improvement in the detection
of specific cancer cells. Despite a negative 5% offset in the capture yield that is presumably
due to imperfections in affinity or centrifugation after the RBC lysing step, the
experimental result in Figure 3.7(c) is in good agreement with the simulated data in Figure
3.7(b) and confirms the optimal flow rate suggested by the simulations.
Dual-magnet mode. The magnetic force attracting bead-bound cells down to the chip
surface results in a number of free beads that land between the apertures and therefore
remain on the chip instead of being immediately cleared out. A simple modification to the
setup clears these free beads out by perturbing the total magnetic field with a second
magnet (whose polarity is aligned for attraction to the primary magnet) situated on top of
the chamber. Manually moving this magnet horizontally in an oscillatory fashion perturbs
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the horizontal magnetic force on the beads and hence leads them to the bottom chamber
through the apertures.
We built a computational model in order to quantitatively explain the effects of this
modification. The analysis was performed under the assumption of zero flow rate since it
focuses on the beads that have already been captured on the chip surface. Figure 3.8 (a)
shows the magnetic flux density distribution in the chamber when the top magnet
(3/16”×3/16”×3/16”) is aligned with the center of the bottom magnet (1/4”×1/4”×1/4”), as
well as when it is located to the left of the bottom magnet. The corresponding magnetic
forces applied on a bead with respect to its position on the chip are shown in Figure 3.8 (b).
The simulation result shows that the horizontal motion of the top magnet causes significant
changes in the magnetic flux density distribution, which alters the magnetic force induced
on the beads in the chamber, especially in the horizontal direction. As a result, the free
beads located in between the apertures on the chip move horizontally along with the motion
of the top magnet. We simulated the horizontal motion of a bead located on the surface of
the central region of the chip and observed that a 3 mm sideways motion of the top magnet
caused the bead to move by 150 µm which is sufficient to lead it to an aperture to be pulled
down by the vertical magnetic force. Figure 3.8 (c) demonstrates the simulated motion of
a bead located at the center of the micro-aperture chip. The bead reached an adjacent
aperture and fell through it with only a 200 µm motion of the top magnet. Therefore,
moving the top magnet by as much as a few millimeters should effectively clear out most
of the free beads that do not initially coincide with an aperture (Figure 3.8 (d)(e)). It is also
plausible that the dual magnet configuration can help clear out the unwanted bead-bound
blood cells that are smaller than 8 μm and hence result in higher purity.
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Figure 3.8. (a) The simulated magnetic flux density of the dual magnet configuration and
(b) the corresponding magnetic force applied on a single bead in the fluidic chamber. (c)
Schematic illustrating the motion of a bead located at the center of the micro-chip with
respective to the movement of the top magnet. The 10 µm lateral displacement of the
bead is resulted from the 200 µm lateral movement of the top magnet. The schematic was
not drawn to scale. (d) (e) Micrographs of chip surfaces without and with the use of a
second magnet after capture to clear out the free beads. Scale bars indicate 56 μm.
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3.3.2

System Characterization by Detecting MCF-7 Cells

Following simulation, the system's ability to recognize and capture tumor cells
spiked into blood samples of healthy humans was experimentally investigated. We
spiked known numbers (0, 8, 10, 20, 30, 40, 50, 60, 70, 100, and 110) of MCF-7
cells into 8 mL of blood, and captured them using anti-EpCAM beads.
Based on the computational study and the experiments discussed above, ideally
around 95% of the spiked tumor cells could encounter the chip surface when the
sample mixture flows through the chamber at 2 mL/min. However, the actual
detection yield is expected to be lower because of a number of factors. For example,
some cells could be lost during centrifugation after RBC lysing step or during
incubation with beads, also the binding efficiency between MCF-7 cells and
antibody-beads could be impeded due to the complexity of the binding environment.
It is therefore important to minimize additional losses once the bead-bound cells are
introduced into the chamber. The high flow rate capability of our system allows us
to quickly circulate the sample mixture multiple times and help maximize the
chances of recovering a cell that may have skipped the chip surface during its first
pass. We therefore circulated the sample at 2 mL/min for 3 minutes, equivalent to
passing it through the chamber 4 times over.
Using fluorescence analysis as described in section 3.2.3, enumeration of the
detected tumor cells was performed manually by capturing images of different
segments of the chip surface and counting the cells in each segment. A plot of the
number of cells detected vs. number of those spiked is shown in Figure 3.9 (b). The
slope of the linear fit shows that the system can detect cells with an 89% detection
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yield and the fairly linear nature of the relationship shows that the system robustly
delivers this efficiency at a wide range of cell concentrations – relevant to rare cell
detection.

Figure 3.9. (a) Bright-field and fluorescent images of cells detected from MCF-7-spiked
blood. MCF-7 cells are stained with CK-FITC and thus show green fluorescence; while
WBCs are stained with CD45-PE and show red. Scale bar indicates 24μm. The contrast
of the fluorescent images has been enhanced artificially. (b) Number of MCF-7 cells
detected vs. number of those spiked in blood.
3.3.3

Detection of CTCs from Cancer Patient Samples

After characterizing the system by detecting MCF-7, we detected CTCs in the
blood samples obtained from patients with advanced cancer. Blood samples
collected from a total of 50 patients with non-small cell lung cancer (NSCLC, n =
38) and pancreatic cancer (PANC, n = 12) were tested using our system. All of the
patients had stage IV metastatic diseases and 20 of the NSCLC patients and 5 of the
PANC patients had not received systemic treatment. 4 to 8 mL of blood from each
patient was examined following the same protocol used in detection of MCF-7 cells
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spiked in blood except for the choice of the antibody-beads. Unlike the cancer cell
lines that are always cultured in a simple and controlled laboratory environment, the
CTCs from patients may vary in their expression and affinity for the EpCAM
antibody.
We used a combination of beads conjugated with different antibodies to target
multiple antigens overexpressed on CTCs. A combination of beads conjugated with
anti-EpCAM, anti-EGFR and anti-VMT at a ratio of 1:1 was used to test NSCLC
samples; while a combination of anti-EpCAM and anti-CEA beads (1:1) were used
for PANC samples. The anti-EGFR and anti-CEA were used to target an extra
antigen (other than EpCAM) that could possibly be overexpressed on CTCs in lung
and pancreatic cancers, respectively. On the other hand, anti-VMT beads were used
to target any CTCs that may be going through epithelial-mesenchymal transition.
The number of CTCs per 8 mL of blood of each patient is shown in Figure 3.10.
We identified CTCs in 49 of 50 patients. Only one PANC patient that had received
chemotherapy recently did not show any CTCs. The number of CTCs detected
ranged from 2 to 122 per 8 mL for NSCLC and 0 to 42 per 8 mL for PANC, resulting
in a mean and standard deviation of 39 ± 32 CTCs/8 mL for NSCLC and 26 ± 11
CTCs/8 mL for PANC.
We further grouped the number of CTCs detected from patients who had received
systemic cancer treatments as well as from those who had not and plotted them in
Figure 3.10. On average we detected 55 CTCs in the blood samples of untreated
NSCLC patients and 21 in those of treated ones; meanwhile, the average CTC counts
of the untreated and treated PANC patients are 31 and 22. A student t-test analysis
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on the two groups of NSCLC patients revealed a p-value of 0.00045, indicating a
statistically significant difference between the CTC counts of the two groups. On
the other hand, presumably due to relatively smaller sample size, the p-value of the
average count between the treated and untreated PANC data is 0.13114 indicating
that the difference is statistically insignificant.

(a)

(b)
Figure 3.10. (a) Histograms showing number of CTCs detected from each of the 50
patients. (b) The mean, standard deviation and p-value of number of CTCs detected from
treated and untreated patients.
3.4

Discussion

In Chapter 3, a second-generation system featured by a micro-aperture chip was
presented for CTC detection. This system integrated a micro-aperture chip to spatially
separate captured cells from free beads. The micro-aperture chip was fabricated using
conventional clean-room manufacturing techniques (photolithography, DRIE, plasma Etch,
wet Etch). Cells captured can be imaged and enumerated directly on the micro-aperture
chip. To numerically study the system’s performance in detecting and separating cells and
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molecules, finite element analysis (FEA) tool was used to analyze factors such as flow rate,
number of beads per cell, as well as dual-magnet mode. By tuning the flow velocity, a
working window has been found to efficiently detect cancer cell without nonspecifically
capturing WBCs. The optimal flow rate for CTC detection was found to be 2 mL/min based
on a computational model that was also verified experimentally. We have observed that in
general MCF7 cells bind to fewer beads than KB cells and hence the lower optimal flow
rate of 2 mL/min (vs. 3 mL/min) is reasonable. With the optimized flow rate, 89% of the
MCF-7 cells spiked in 8 mL of blood were detected. This system was further applied to
process clinical samples obtained from NSCLC and PANC patients using combination of
antibody-beads and have detected CTCs in all 38 NSCLC patients and 11 of 12 PANC
patients. Moreover, the data demonstrated a statistically significant difference in the
number of CTCs between treated and untreated NSCLC patients, which warrants further
analyses and studying of the correlation between the CTCs detected by this system and the
overall tumor burden. Those results confirmed that the second-generation system, with a
stronger ability to process large amount of beads, achieved a higher cell detection yield
compared to the first generation system. Also, interference induced by free beads can be
significantly minimized so high-quality enumeration of captured cells can be realized.
Another major advantage second-generation system over the first-generation system is
more than two types of analytes can be detected to further improve the detection efficiency.
Therefore, in Chapter 4 we will further exploit this system’s capability in simultaneously
detecting both cell and molecule cancer biomarkers.
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CHAPTER 4. SECOND-GENERATION SYSTEM FOR SEPARATION AND DUAL
DETECTION OF PROSTATE CANCER MARKERS
4.1

Introduction

In previous chapter, the development of the micro-aperture (i.e. second-generation)
system, and its testing in the context of detecting whole cells was described. This chapter
focuses on further development and adaptation of the same system to detection of both
cells and molecules from the same sample and at the same time. As described before,
detecting both cellular as well as molecular markers of cancer can provide more complete
and complementary information about the progression of the disease. To put our device
into context, we chose prostate cancer where dual molecular/cellular detection can be
especially useful. Prostate cancer is the most commonly occurring cancer for men in the
United States. In 2016 alone, the estimated numbers of newly diagnosed cases and deaths
due to prostate cancer are 180,890 and 26,120, respectively [85]. In an effort to reduce the
impact of prostate cancer on society, there has been a major push towards early detection
strategies to help stop the disease before it becomes life threatening. Critical to this effort
is the discovery and validation of biomarkers (e.g. proteins, DNA, metabolites, cells, etc.)
which is of great significance not only because these analytes are important for early
diagnostic screening tests, but also due to their roles in establishing prognosis and
monitoring response to therapy, among other uses [2, 6-9]. While multiple biomarkers have
been investigated for the detection of prostate cancer, including prostate specific membrane
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antigen (PSMA), micro-RNA, and survivin, the most commonly used biomarker for
diagnosing prostate cancer is the protein, prostate specific antigen (PSA) [86-88]. PSA is
detectable via a number of available and highly sensitive assays [89]. However, the
extensive use of diagnostic screening tests based primarily on PSA are controversial, so
much so, that in 2012 the United States Preventive Task Force concluded that the risks of
such routine blood tests (e.g. unneeded surgery and radiation) outweighed the benefits of
early detection and thus recommended reduced testing [90]. This has led to the search for
additional biomarker candidates that can better stratify different disease states.
CTCs or circulating tumor cells have been extensively studied and validated for use in
prostate cancer [21, 22]. CTC biomarkers are commonly isolated via immuno-magnetic
bead-based separation assays by targeting specific cell-surface markers such as EpCAM,
cytokeratin, PSMA, vimentin, and others [91-94]. Prostate CTCs have recently been found
to be correlated with a number of other recognized targets (e.g. lactate dehydrogenase,
alkaline phosphatase, PSA) and used in combination for treatment monitoring and survival
prediction of prostate cancer patients [95, 96]. For example, the use of the CellSearch
platform for CTC detection combined with a real-time quantitative polymerase chain
reaction (RT-qPCR) assay enabled an approach consisting of CTC enumeration and stem
cell gene expression analysis to be applied and used to determine the prognosis and predict
treatment outcomes in a metastatic castration-resistant prostate cancer model [97]. This
example demonstrates the need and advantage of developing biomarker panels via
multiplexed target analysis. However, the widespread implementation of such multiplex
analysis requires overcoming several barriers and limitations [1, 2, 10-12]. These include
inter-individual variability, reliability, sensitivity and specificity during analyte detection,

82
all of which have led to significant measurement deviations [98]. Additionally, multiple
biomarker platforms are often employed to perform numerous individual tests, often at
great expense, in order to provide sufficient reliable information for patient evaluation [1315, 92]. This has led to the need for high-throughput detection platforms capable of
analyzing multiple biomarkers simultaneously from a single sample.
Several commercial high-throughput platforms for multiplexed protein analysis are
widely available (e.g. Luminex, MSD) and academic groups along with industry are
actively pursuing methods for the detection and analysis of cancer cells (e.g. CTCs) from
large sample volumes. However, it is not ideal to measure proteins or cells, separately,
which is the case with most biosensor platforms [7, 37, 81, 99-103]. As the CTC capture
and stem cell gene expression study above illustrated, valuable information can be gathered
from both cellular and molecular biomarkers. Additionally, by more accurately correlating
molecular biomarker concentrations in a sample fluid with specific cell populations present,
which would be possible with a dual-detection platform, new biomarker panels could be
developed to better describe a patient’s disease state and provide a more holistic analysis
[29]. Analyzing a single sample for multiple target types – cells and molecules – should
also lead to reduced sample-to-sample variation [104-106].
In Chapter 2, we introduced the first-generation system capable of concurrently detecting
cellular and molecular markers, in high throughput, from a single sample fluid. This device
utilized a glass slide integrated with a magnet for attracting cellular and molecular
biomarkers bound to antibody-conjugated magnetic beads [107]. While this preliminary
system successfully demonstrated the ability to simultaneously detect cellular and
molecular targets from an ovarian cancer patient sample (ascites fluid), several limitations
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were observed. As discussed in section 3.1 (Figure 3.3), these limits include captured cells
being buried under bead clusters, which was exacerbated when higher bead concentrations
were used. The clusters of beads on top of cells reduced the cell purity (especially for
fluorescence imaging purposes) and the combination of captured cells and molecular
markers, with any remaining beads, all on the same surface also reduced the ability to
retrieve the cells for downstream analysis (e.g. genetic sequencing, culturing, etc). As the
concentration of CTCs in patient samples are very low, the inability to increase the bead
amount conversely affected the ability for multiplexed ligand targeting, which could be
used for not only capturing additional protein/molecular analytes but also for increasing
the number of CTCs detected. Therefore, in Chapter 3 we have developed the secondgeneration system that combines rapid fluid flow with size-based separation to achieve a
high-throughput immuno-magnetic detection platform and applied this system to capture
CTCs from breast cancer patient blood. However, at that stage only the cell detection has
been realized.
In this chapter, we further develop the second-generation system for the simultaneous
separation and detection of molecular and cellular targets. The new version divides
magnetically captured cellular and molecular targets into upper and lower chambers,
respectively, via the use of a silicon chip containing 6 µm diameter micro-aperture holes.
Upon incubating a liquid sample with antibody-conjugated magnetic beads targeting
desired cells and protein biomarkers, the sample is then flowed through the upper chamber
of the device. The integration of an external magnetic force with the micro-aperture chip
allows the larger cell-bead complexes (>10 µm) to be trapped on top of the chip, with the
smaller protein-bead complexes (1 µm) and remaining beads passing through the micro-
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aperture holes into the lower chamber where the magnetic force holds them in place on a
bottom surface. In this chapter, we decreased the micro-aperture size from 8 µm to 6 µm
because we try to keep extremely small CTCs from being squeezed into the holes and
dropping down to the lower chamber.
As already mentioned in Chapter 3, there are multiple advantages of the new generation
device over the first-generation system. First, due to the efficient elimination of non-cell
complexed beads from the upper chamber, both captured cells and molecules can be
analyzed separately without mutual interference [81]. The cells can be quantified directly
on chip and then removed for further investigation. Protein-bound beads can be retrieved
from the bottom chamber and analyzed using fluorescence-based detection or with other
commercially available assays. Lastly, this design enables the use of higher bead
concentrations.

The detection strategy (Figure 4.1) is similar to what has been discussed in Chapter
2. Super-paramagnetic streptavidin coated microparticles are first conjugated to
their corresponding biotinylated polyclonal antibodies. A sample fluid containing
spiked model prostate cancer “LNCaP” cells and prostate specific membrane
antigen or “PSMA” protein (Figure 4.1 (a)) is then combined with the antibody
conjugated-bead (anti-bead) mixture and incubated for 90 min using an end-overend rotator.
The microfluidic device is divided into two parallel chambers separated by a
micro-aperture chip composed of an array of 6 µm diameter micro-apertures
(2.6×105 holes in total). Following sample incubation, the mixture is flowed through
the upper chamber (Figure 4.1 (b)) at a flow rate of 2 mL/min and circulated for 4
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min. A permanent magnet positioned beneath the device provides the magnetic field to
pull the bead-bound cells and proteins, as well as free beads, towards the micro-aperture
chip. The protein-bead complexes and free beads, owing to their smaller size (1 µm), can
be drawn down to the lower chamber through the micro-apertures whereas cell-bead
complexes, due to their larger size (>10 µm), are retained on top of the micro-aperture chip
in the upper chamber. The cell and molecular targets, in the upper and lower chambers,
respectively, are then subjected to separate fluorescence-based quantitative assays. The
cells are enumerated on the chip surface. The protein-bound beads are retrieved from the
lower chamber by introducing washing buffer with the magnet removed and then analyzed
via fluorescence microscopy.

(a)

Figure 4.1. Schematic diagram of detection strategy. (a) Rare cells and proteins are
simultaneously captured by streptavidin-coated magnetic beads conjugated with
antibodies. (b) Sample is flowed through the upper chamber in which captured cells and
proteins are size-separated via the micro-aperture chip. Cells can be directly quantified on
chip whereas beads are retrieved, by introducing wash buffer with magnet removed, for
analysis off chip.
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(b)

Figure 4.1. Continued
This chapter first presents the device assembly and operation, followed by numerical
modeling. Next, multiple ligands conjugated to magnetic beads are investigated to achieve
maximal cell capture yield. Using culture media, the limit of detection for PSMA as well
as the performance in dual analyte capture is then determined. Finally, the potential of the
device for clinical applications is demonstrated using diluted human blood spiked with
PSMA and LNCaP cell targets, to mimic prostate CTCs and protein biomarkers from a
patient sample.
4.2

Materials and Methods

In this chapter, we characterized the new device for dual detection using a prostate cancer
model, PSMA free-protein and LNCaP cells, with two antibodies, anti-PSMA and antiEpCAM [108, 109]. EpCAM and PSMA cell surface markers have been previously used
to isolate prostate cancer CTCs [110]. The LNCaP cell line is a commonly applied model
for prostate cancer and has been shown to express both EpCAM and PSMA antigens on
the cell surface, making it particularly relevant to our work [111-113]. As EpCAM is one
of the most commonly used markers for capturing CTCs in breast, colon, and prostate
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cancers, its use with LNCaP cells also enables the device characterization to be more
generalized to other diseases [114]. The cell-free PSMA protein was chosen due to its value,
from an analytical perspective, to challenge the new device by using a free-protein

target that is also on the surface of the cell, in combination with a ligand (EpCAM)
specifically targeting only the cell itself. This contrasts with the scenario in which
the free-protein and cells would be captured using completely different antibodies.
While the presence of PSMA free-protein in circulation has been studied, the clinical
significance of detecting PSMA alone for prostate cancer remains uncertain [115,
116]. Thus, a method to simultaneously detect free-PSMA protein as well as prostate
cancer cells might allow for new diagnostic value for PSMA.
4.2.1

System and Device Assembly

The microfluidic device consists of eight components: acrylic cover, acrylic stand,
top fluid cover, bottom fluid cover, top fluid spacer (PDMS Spacer I), bottom fluid
spacer (PDMS Spacer II), micro-aperture chip, and magnet. The assembling scheme
is shown in Figure 4.2 (a). The top fluid chamber was constructed by placing a layer
of PDMS (thickness ~1.0 mm) on the micro-aperture chip, to serve as a spacer, and
then mounting a 1 mm-thick glass slide on top of it. A laser cutter (Universal Laser
System, Inc. Professional Series) was used to define the dimensions (30 mm by 3.8
mm) of the PDMS channel such that it enclosed the porous area (8560 µm by 2750

µm) of the micro-aperture chip. The chip (thickness of 550 μm) with a porous area

of 6 μm diameter micro-aperture arrays was fabricated following the procedures
described in a previous publication [84]. The inlet and outlet for the upper chamber
were formed by drilling holes through the glass slide using a diamond rotary bit.
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Tubing was sealed in place with epoxy. The bottom chamber was constructed with
another PDMS layer (thickness ~0.2 mm) containing a channel (30 mm by 3.8 mm)
fabricated with the laser cutter. The lower channel was sealed using a transparency
sheet (3M PP2500, 0.1 mm thick). For the transparency sheet, the inlet and outlet
holes were fabricated using the laser cutter. The bottom inlet and outlet tubing was
connected to plastic elbow fittings and glued to the holes of the transparency sheet
using epoxy. The assembled components were then mounted on an acrylic stand
containing three cut-out rectangular openings. The middle opening was for inserting
the magnet while the two openings on both sides provided space for the inlet and
outlet tubing to emerge from the bottom chamber. All acrylic components were
modified using the laser cutter. The top acrylic cover also contained a wide cut-out
to enable quantification of cells directly on the chip surface using a fluorescence
microscope.

Figure 4.2. Device assembly. (a) Exploded view of assembly scheme. (b) The assembled
device. (c) SEM image of the micro-aperture chip containing an array of 6 µm diameter
micro-apertures.
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4.2.2

Device Modeling

COMSOL was used to model the influence of the micro-aperture chip surface on
the magnetic bead trajectories. This was performed to quantify the number of beads
that pass through the micro-apertures into the bottom chamber while flowing the
solution through the upper chamber of the device. All other simulation details,
equations and conditions are similar to that in Chapters 2 and 3 [81, 107]. To
simplify the modelling, only beads without cells were used for the simulations – the
possibility of cells passing through holes via contortion or other shape modification
was neglected.
4.2.3

Experimental Setup

As described in “System and Device Assembly”, two sets of inlets and outlets
provided access to the top and bottom chambers. After priming the upper and lower
chambers with PBS buffer, the bottom inlet and outlet were sealed. The top inlet
was then connected to the sample source and the top outlet was connected to a
peristaltic pump (New Era Pump Systems, NE-9000). This allowed the sample/bead
mixture and buffer to only flow through the top chamber of the device. In order to
retrieve and collect the protein-bead complexes from the bottom chamber for
downstream analysis following an experiment, the top inlet and outlet tubes were
sealed, the bottom inlet tube was connected to the washing buffer (PBS) and the
bottom outlet tube was connected to the pump. With the magnet removed, the beads
could then be collected in a plastic tube at the outlet of the pump by flowing 1.5 mL
of buffer.
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Prior to running any experiments, PBS-T (PBS containing Tween 20) plus bovine
serum albumin (BSA) was used to block the solution-exposed surfaces of the device.
The blocking solution consisted of 600 µL of 20x PBS-T (Thermo Fisher Scientific,
USA), 400 µL of 30% BSA in PBS (Sigma, USA), and 11 mL of DI water. About
200 µL of this solution was injected into the upper chamber of the device and
incubated for 3 hours at room temperature. Both the bottom and top chambers were
then flushed with PBS.
4.2.4

Preparation of LNCaP Cells and PSMA Protein Solution

LNCaP cells, purchased from American Type Culture Collection, were cultured in
RPMI 1640 media (Gibco, USA) containing 10% fetal bovine serum (FBS, Gemini
Bio Products). To harvest LNCaP cells, they were first released from a culture flask
using a Trypsin-EDTA solution (Invitrogen) and then re-suspended in culture
medium. The cell concentration was measured by taking 5 samples (each with a
volume of 3 µL, ejected onto a microscope slide) and manually counting the cell
number using a bright-field microscope to obtain the average. The cell suspensions
were then subsequently spiked into 1 mL of medium (or diluted blood) to achieve
the desired concentration.
Recombinant human PSMA/FOLH1 protein (PSMA) was purchased from R&D
systems and stored at -20℃ at a concentration of 0.5 mg/mL in PBS. PSMA was
then diluted and spiked into medium or diluted human blood at desired
concentrations.
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4.2.5

Preparation of Antibody-coupled Magnetic Beads

Biotinylated polyclonal anti-PSMA, anti-EpCAM, and anti-EGFR were all
purchased from R&D Systems and stored at a concentration of 0.2 mg/mL in PBS.
Prior to detection, the desired antibody was conjugated to micro-beads by incubating
the antibody (10 µL) with streptavidin-coated 1 µm magnetic beads (20 µL, 10
mg/mL, Sigma Aldrich) in phosphate buffered saline (PBS) at room temperature for
60 min on an end-over-end rotator. An excess amount of antibody was used to ensure
saturation of binding sites on the bead surface. Following incubation, the beads were
washed 3 times with PBS using a magnetic stand (PerkinElmer, Germany) and then
stored at 2 mg/mL.
4.2.6

Detection of LNCaP Cells in the Absence of Free PSMA

The device was initially tested with multiple antibody-conjugated magnetic beads
to determine which ligands and quantity of beads provided the highest capture of
LNCaP cells. The new device enabled the doubling of the 1 µm bead amount able
to be used in an assay, from 40 µg in the previous design to 80 µg [107]. This was
due to the ability to clear the excess beads into the lower chamber. In these
experiments, ~100 LNCaP cells were spiked into 1 mL of culture medium. The
spiked samples were then incubated with either 40 µg (20 µL) or 80 µg (40 µL) of
antibody beads at room temperature for 90 min using an end-over-end rotator. If a
single antibody was used then 20 µL or 40 µL of only that bead solution (2 mg/mL)
was added. If two antibodies were used, then 20 µL of each antibody bead solution
was added. The sample was then circulated in the upper chamber of the device (with
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the bottom magnet in place) at a flow rate of 2 mL/min for 4 minutes followed by
washing with 2 mL of PBS.
Following detection, any free-beads which remained on the micro-aperture chip
surface were gathered into the bottom chamber using a dual-magnet mode as
discussed in Chapter 3 [81]. After that, with only the bottom magnet in place, the
captured cells were then directly fixed on the chip using a 4% paraformaldehyde
(PFA) solution in PBS followed by fluorescent tagging for confirmation. To label
the cells, monoclonal antibodies against PSMA conjugated with PE (anti-PSMA-PE,
Miltenyi Biotec, USA), anti-pan Cytokeratin monoclonal antibodies conjugated to
FITC (anti-CK-FITC, Miltenyi Biotec, USA), and 4',6-diamidino-2-phenylindole
(DAPI, Sigma-Aldrich, USA) were introduced into the chamber all at once and
incubated for 30 minutes at room temperature. Unbound labels were washed out
with 3 mL of PBS. The micro-aperture chip was then inspected while still in the
microfluidic device, using a fluorescence microscope (ECLIPSE 80i, Nikon)
containing a fibre illuminator (C-HGFI, Nikon), to count the captured cells and
determine the capture efficiency.
4.2.7

Detection of Free PSMA in the Absence of LNCaP Cells

The detection of free-PSMA (without LNCaP cells) was performed identically to
that above for LNCaP cells without PSMA but with the following modification. For
these experiments, only PSMA was spiked (0 – 12.5 nM, 0 – 1000 ng/mL) into 1
mL of culture media. Following detection, the dual-magnet mode, as described
above, was used in order to gather PSMA-bound beads and free-beads into the
bottom chamber. Both magnets were then removed and 1.5 mL of PBS was
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introduced into the bottom chamber at a flow rate of 1.5 mL/min to wash out the
beads, which were collected in a plastic tube.
These beads were then analysed by flowing the collected suspension into a
chamber containing a glass slide with a magnet placed underneath for immunofluorescence analysis (Figure 4.3). Prior to analyzing the samples and in order to
prevent non-specific binding of antibodies, a PBS solution containing 0.05%
Tween-20 and 1% BSA was introduced into the single-chamber device and allowed
to incubate for 3 hours at room temperature. The device was then washed with 2 mL
of PBS at a flow rate of 3 mL/min. Retrieved beads were injected into the chamber
and distributed over the chamber’s glass surface, and held in place by the external
magnetic force. PSMA was subsequently stained with anti-PSMA-PE (1:20 dilution
in PBS) and incubated under static conditions at room temperature for 30 minutes,
followed by washing with 3 mL of PBS. Finally, the chamber was inspected using
the fluorescence microscope for PSMA quantification [107].

Figure 4.3. Schematic diagram of single-layer system for bead-based molecule
fluorescent imaging.
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4.2.8

Dual Detection of LNCaP Cells and PSMA

The combined detection of LNCaP cells and PSMA from culture media was
performed next. Here, a series of suspensions were prepared by spiking ~100 LNCaP
cells and PSMA with various concentrations from 0 to 12.5 nM (0 – 1000 ng/mL)
into 1 mL of culture medium. The samples were then incubated using the optimal
antibody bead composition and analysed according to the two previous sections.

For detection in human blood, 1 mL of diluted blood (blood:PBS (1:3)) was
prepared and used within 2 hours after being collected from healthy volunteers under
an approved IRB protocol. Blood samples were first drawn into BD vacutainer tubes
containing sodium poly(anethol) sulfonate as the anti-coagulant prior to being
diluted. For these experiments, LNCaP cells and/or free PSMA (in addition to the level
of PSMA naturally present) were spiked into each sample. Four conditions were tested: (1)
a blank without any added target protein or cells; (2) ~27 added LNCaP cells; (3) ~27 added
LNCaP cells and 50 pM (4 ng/mL) of PSMA. (4) ~54 added LNCaP cells and 1.25 nM
(100 ng/mL) of PSMA. It should be noted that the spiked PSMA concentrations provided
are relative to the 1 mL diluted sample volume.
The diluted blood samples were then analyszd similar to that for dual detection from
media but with the following modifications. Prior to fixing the cells using PFA but after
removing the beads from the bottom chamber, red blood cell (RBC) lysis buffer (G-

Biosciences, U.S.A.) was introduced into the upper chamber and incubated for 5 min
before rinsing with PBS. This was done in order to remove RBCs which were
attracted to the magnet during the sample circulation step. Additionally, anti-CD45PE was added to the dye cocktail for cell labelling in order to differentiate any white
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blood cells (WBCs) that might be present due to non-specific binding. Anti-PSMAPE was removed from the dye cocktail so it would not overlap with the anti-CD45PE signal due to their identical fluorescent labels (i.e. Phycoerythrin (PE)).
4.3
4.3.1

Results and Discussion
Modeling the Effect of the Micro-aperture Chip for Magnetic Bead Capture

In previous chapters, we used simulations to investigate how flow rate and the
number of beads bound per cell would influence the trajectories of cell-bead
complexes in our microfluidic device [81, 107]. It was assumed in Chapter 3 that
the micro-aperture chip functioned as a solid surface (without pores) with respect to
its ability to capture bead-bound cells. Finite element analysis software (COMSOL)
was used to simulate the magnetic field, flow field, induced magnetic force and fluid
drag force, as well as the gravity and buoyant forces acting on cells and magnetic
beads [81]. Here, we extended our characterization to account for the true 6 µm
diameter micro-aperture array structure in order to determine the quantitative effect
of the structure on the ability of protein-bead complexes and free beads to fall into
the lower chamber of the device during sample flow.
For this work, the magnetization effect of particles on one another, the difference
between a protein-bound bead and a free bead, and the effect of pore-depth of the microaperture chip on the bead were all assumed to be negligible. It was also assumed that the
beads were randomly distributed over the inlet cross-section as they were introduced into
the chamber. Due to the low Reynolds number (

= 9.95) within the device, laminar flow

was used for the simulation and the flow rate was set to 2 mL/min in accordance with

previous experiments and simulations [81, 107].
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Figure 4.4 shows the simulation and trajectories of 100 super-paramagnetic beads
flowing inside the dual-chamber system. According to the results, a uniform flow field was
quickly established following the introduction of beads into the upper chamber.
Subsequently, 52% of the beads ended up in the bottom chamber via the micro-aperture
holes. This implied that, in order to aid in the visualization of cells in the upper chamber
for actual experiments, a dual-magnet mode was going to be necessary. This allows any
remaining free beads on the micro-aperture chip surface to move laterally, find a hole, and
fall into the bottom chamber [81].

Figure 4.4. Bead trajectory simulation results. (a) The flow field in the device with the
inlet flow rate set to 2 mL/min. (b) Trajectories of magnetic beads in the dual-chamber
system showing that 52% of the beads will fall through the micro-aperture holes during
flow, indicating the need for a dual-magnet mode to aid in the removal of the remaining
protein-bound beads and free beads that land on the chip surface.
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4.3.2

Cell Detection in the Absence of Free PSMA

Beads conjugated with various antibodies were used to characterize the ability of
the micro-aperture device for detecting rare cells without free protein present. As
LNCaP cells are known for expressing significant amounts of both PSMA and EpCAM
surface markers, corresponding antibodies to these two antigens were initially investigated
[117]. Using two quantities of magnetic beads (40 µg and 80µg) for each target, antibody
bead conjugates were prepared and tested in order to achieve the highest cell detection

yield. Captured cells were verified based on a combination of factors including their size
(10-30 µm), shape (close to circular), and fluorescence signals, wherein anti-PSMA-PE (+),
anti-CK-FITC (+) and DAPI (+) cells were scored as a positive result (Figure 4.5).

Figure 4.5. Fluorescence images of LNCaP cells. Single cell (row 1), two cells (row 2),
and three cells (row 3) were stained with anti-PSMA-PE, anti-CK-FITC, and DAPI to
verify the identification of the LNCaP cells captured.
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As shown in Figure 4.6 a, both quantities of anti-PSMA-only beads led to a
detection yield of ~50% of the spiked LNCaP cells. For EpCAM, while the average
capture value for 80 µg of beads was higher than that for 40 µg (96% versus 88%),
from a statistical perspective, the difference was not significant (p > 0.05). The
higher capture for EpCAM compared to PSMA correlates with a higher level of
expression for the former, which was confirmed using a fluorescence cell-labeling
assay (Figure 4.6 (b)). These results indicated a level of expression for EpCAM that
was about twice that of PSMA. As the goal of this work was to achieve dual
detection of LNCaP cells and free PSMA protein, a 50% mixture of anti-EpCAM
and anti-PSMA bead conjugates was then tested (40 µg of each). The data revealed
that this combination was able to achieve the same high yield (~94%) as compared
to using only anti-EpCAM beads. Thus, the presence of anti-PSMA did not interfere
with the capture efficiency. It should be noted that since LNCaP cells express both
surface antigens, it is possible that both antibody beads play a role in cell capture,
especially due to the heterogeneous nature of cell populations [118]. For example, a
small number of cells within the population may express more PSMA than EpCAM.
However, anti-EpCAM, due to being significantly more expressed overall, is likely
the major contributor to the high yield obtained for the bead mixture.
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(a)

(b)

(c)

(d)

Figure 4.6. (a) LNCaP cell capture efficiency using different anti-bead combinations and
bead quantities. Blue and red bars represent 40 µg and 80 µg, respectively, of total beads
added to the cell-spiked media. In the case where a mixture of beads was used (EpCAM
plus PSMA), 40 µg of each bead was added. Error bars represent one standard deviation
based on three experiments. (b) (c) Relative staining ratios for corresponding antigens
expressed on LNCaP (b) and KB (c). (d) Detection efficiency of LNCaP cells and KB
cells using combination of anti-beads (40 µg of anti-PSMA beads + 40 µg of antiEpCAM beads).
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In order to verify the specificity of PSMA and EpCAM ligands and to ensure that
the antibody conjugated beads were not non-specifically capturing LNCaP cells, an
antibody against one additional surface marker, epidermal growth factor receptor
(EGFR), was tested as a negative control. Previous reports have indicated that
LNCaP cells do not exhibit high levels of EGFR, which was also confirmed by our
fluorescence staining experiments (Figure 4.6 (b)) [119]. The results shown in
Figure 4.6 (a) for anti-EGFR conjugated beads provide further evidence that LNCaP
cells express very little EGFR as only ~7% detection yield was achieved, for both
amounts of beads tested.
To further validate the specificity of the PSMA and EpCAM antibody bead
combination for our cellular targets, KB cells, a type of epithelial cancer cell line
known for expressing high levels of folate receptor (FR) but no significant amounts
of PSMA [120] or EpCAM (Figure 4.6 (c)), were used as an additional negative
control. Compared to LNCaP cells, KB cells were found to be captured significantly
less with the anti-PSMA and anti-EpCAM bead combination (95% versus 9% in
Figure 4.6 (d)). This confirmed that the anti-PSMA and anti-EpCAM bead mixture
is able to achieve high capture efficiency of cells that over-express specific surface
antigens. It should be mentioned that 9% (instead of 0%) of KB cells were captured
because KB, due to being epithelial in nature, expresses some amount of EpCAM
on the cell surface [121].
While a ~94% capture yield for LNCaP cells using a mixture of anti-PSMA and
anti-EpCAM beads was achieved, there were still 6% which were not detected. Thus,
we investigated whether these uncaptured cells passed through the micro-apertures
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into the bottom chamber. Following the detection of LNCaP cells on the microaperture chip surface, the bottom chamber was inspected using a bright-field
microscope in order to observe the lower chamber surface (i.e. the transparent film)
as well as the bottom of the micro-aperture holes – no cells were found. This
indicates that the small number of uncaptured cells might have been lost due to the
heterogeneous nature of the cell population, with several cells not expressing a
sufficient amount of either PSMA or EpCAM antigen to enable a magnetic pull
down to the micro-aperture surface. While expected to be minimal, it is also possible
that some cells may have stuck to the walls of the sample tube or the tubing used in
the fluidic system and hence may have been lost.
4.3.3

Detection of Free PSMA in the Absence of LNCaP Cells

Next, the ability of the micro-aperture device to detect free proteins in the absence
of cells was evaluated. Using the same procedures and conditions as for cell
detection, different concentrations of free PSMA (0 – 12.5 nM, 0 – 1000 ng/mL)
were spiked into 1 mL of culture medium. The sample was then incubated with a
50% mixture of anti-PSMA and anti-EpCAM beads. Following the capture and
elution of protein-bead complexes and free beads from the lower chamber of the
micro-aperture device, the retrieved beads were subsequently injected into a single
chamber platform for fluorescence analysis. Figure 4.7 shows the fluorescence and
corresponding bright field images of the beads distributed on the single chamber
device glass surface for three different PSMA concentrations: 12.5 nM (1000
ng/mL), 1.25 nM (100 ng/mL), and 0 nM (0 ng/mL). Using these images with
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multiple PSMA spiked concentrations subsequently allowed the limit of detection
(LOD) for the micro-aperture device to be determined.

Figure 4.7. Three pairs of fluorescence (left) and bright-field (right) images collected
from cell media samples spiked with PSMA concentrations of 12.5 nM (1000 ng/mL) (a),
1.25 nM (100 ng/mL) (b), and 0 nM (0 ng/mL) (c).
In order to determine the numerical correlation between the input (PSMA concentration)
and output (fluorescence) signals, we collected fluorescence images of the stained beads
and the corresponding reversed bright-field image from the same observation window
[107]. The fluorescence intensity was then normalized by the intensity of the reversed
bright-field image, which was used as an estimation of the amount of beads in that
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observation window. The normalized intensity, termed the “B-ratio”, thus represents the
fluorescence signal per bead. The B-ratio was measured for eight different PSMA
concentrations ranging from 0 to 12.5 nM (0 – 1000 ng/mL) as shown in Figure 4.8 (a).
Performing a least squares Langmuir Isotherm fit to the experimental data revealed:

B = 0.222 +
where

.

.

is the B-ratio;

(4.1)

⁄

is the PSMA concentration (nM); and 0.222 is the theoretical

bias which is attributed to either non-specific binding between the fluorescent dye and
antibody beads and/or the intrinsic fluorescence background of the magnetic beads. The
theoretical bias agrees with our experimental B-ratio bias of 0.198, which was the observed
response in the absence of PSMA. The intersection of the fitted curve with the backgroundplus-three-standard-deviation line (Figure 4.8 (b)) corresponds to a PSMA spiked
concentration of 34 pM (2.7 ng/mL), which we consider as the LOD for this assay

using the new device. However, lower concentrations were still detectable (albeit
not quantifiable based on our conservative definition of the LOD) using this assay.
The effective dissociation constant (Kd) between anti-PSMA and PSMA was found to be
approximately 3.0 nM, which is in reasonable agreement with previous reports [122, 123].
While the simplicity of the overall method allowed an intensity assay using a fluorescence
microscope to be used to quantify free-protein capture, the ability to easily retrieve the
beads using the new device also enables the future use of other analytical techniques (e.g.
flow cytometry, Luminex) to further expand the versatility and sensitivity of molecular
concentration measurements.
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(a)

(b)

Figure 4.8. (a) The standard detection curve for free-PSMA spiked into cell culture media
using the anti-PSMA and anti-EpCAM bead mixture. The horizontal brown line
represents the experimental background (B-ratio when PSMA = 0 nM) and the green line
represents the background plus three standard deviations. The data reveals a limit of
detection of 34 pM. Error bars indicate one standard deviation from three experiments for
each concentration. (b) Detection limit of PSMA spiked into culture media in the absence
of LNCaP cells.
As different combinations and amounts of antibody beads were analyzed to achieve the
highest cell detection yield, we also investigated the contribution of anti-PSMA and antiEpCAM for binding free PSMA. Here, various antibody bead combinations (80 µg of antiEpCAM only, 80 µg of anti-PSMA only, and 40 µg of anti-EpCAM plus 40 µg of antiPSMA) were tested using several concentrations of PSMA spiked into media (Figure 4.9).
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Figure 4.9. B-ratios of different combinations of antibody beads (anti-EpCAM, antiPSMA plus anti-EpCAM, and anti-PSMA) for detecting multiple concentrations of
PSMA (0 - 12.5 nM) spiked into culture media.
The results showed that anti-PSMA alone achieved the highest recovery, followed by the
mixture of antibody beads. The use of only anti-EpCAM was found to have no significant
effect on the ability to capture PSMA. While using only anti-PSMA beads would possibly
allow for an improvement in the LOD for spiked PSMA, this would come at a loss in cell
detection yield (Figure 4.6 (a)). Thus, in order to achieve the highest yield for dual detection
of cells and PSMA, a 50% bead mixture of anti-PSMA and anti-EpCAM beads was used
for the remainder of this work. However, increasing the micro-aperture array area to
accommodate an even larger number of beads, in a future device design, may lead to
improved LODs for molecular targets while maintaining high cell capture efficiencies.
4.3.4

Dual Detection of LNCaP Cells and Free PSMA Spiked into Media

Next, the capability of the micro-aperture chip system for separating and detecting
both LNCaP cells and free-PSMA from a single solution was tested. For these
experiments, ~100 LNCaP cells and various concentrations (0 - 12.5 nM, 0 – 1000
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ng/mL) of PSMA were spiked into culture medium (1 mL). The cell quantity and
protein concentrations were chosen to be comparable to values reported for healthy
human controls (PSMA only: 1 – 600 ng/mL (16 pM – 7.5 nM)) and prostate cancer
patients (PSMA: 350 – 950 ng/mL (4.38 – 11.9 nM) and CTCs: 0 – 400 per mL of whole
blood) [23, 80, 124-126]. Figure 4.9 shows the measured PSMA concentration

determined by Equation (4.1) (left y-axis) and the percentage of LNCaP cells
captured (right y-axis) as a function of the PSMA concentration spiked into the
media (x-axis). These results reveal several features. First, for PSMA spiked
concentrations from 125 pM to 12.5 nM, the spiked concentrations (x-axis) and the
measured concentrations (left y-axis) matched almost perfectly. However, the next
lowest spiked condition (12.5 pM) was slightly above the measured value as
determined from Equation (4.1). This is likely due to the low resolution in the
detection curve at these spiked concentrations and indicates that our conservative
method to define the LOD (34 pM) as being three standard deviations from the
baseline noise, is reasonable. For the lowest concentration analysed (1.25 pM) in
this particular set of experiments, the measured PSMA value did not significantly
differ from the background response (0 nM). Most importantly, for all samples tested,
the micro-aperture device was able to detect LNCaP cells with a yield of ~93%.
The results from Figure 4.10 confirm that the new device can detect multiple
concentrations of PSMA while also capturing LNCaP cells. Furthermore, they also
indicate that the cell detection yield is not significantly affected by the presence of
free-PSMA. One possible reason, as mentioned above, is that the anti-EpCAM beads
play the dominant role in capturing a majority of the cells. The anti-PSMA beads
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thus play the major role in PSMA protein detection with a secondary benefit of
helping anti-EpCAM in capturing more cells. As an additional check, the microaperture system was further characterized by simultaneously detecting a single
concentration of PSMA (1.25 nM) in the presence of a variable number of LNCaP cells (0
– 80) using the anti-PSMA and anti-EpCAM bead mixture. Subsequent fluorescence
analysis showed that the ability to capture free protein biomarkers was not significantly
affected by the number of target cells present (Figure 4.11).

Figure 4.10. The measured free-PSMA concentration (left y-axis) based on Equation
(4.1) and the detection yield of LNCaP cells (right y-axis) plotted against spiked PSMA
concentration in culture medium (x-axis). Blue dots represent the detected PSMA
concentration while red dots represent the LNCaP detection yield. Error bars indicate one
standard deviation for three measurements.
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Figure 4.11. Measured PSMA concentrations (using Equation (4.1)) which were
concurrently detected from culture media samples containing different numbers of spiked
LNCaP cells and 1.25 nM of added PSMA.
4.3.5

Dual Detection of LNCaP Cells and Free PSMA Spiked into Healthy Human
Blood

In order to demonstrate the potential of the micro-aperture system for the simultaneous
detection of cell and protein targets from clinical samples, LNCaP cells and PSMA were
spiked into diluted healthy human blood which was used to simulate an actual prostate
cancer patient. For these experiments, 250 µL of unprocessed whole blood was first diluted
to 1 mL with PBS and then spiked with LNCaP cells and/or free-PSMA, in addition to the
level of PSMA naturally present. The sample was then incubated using the 50% mixture
of anti-PSMA and anti-EpCAM beads, injected into the micro-aperture device, and
analyzed using similar procedures as above. The measured PSMA concentration was
calculated using Equation (4.1). LNCaP cells were verified based on a combination of
factors including their size (10-30 µm), shape (close to circular), and fluorescent signals,
wherein anti-CK-FITC (+), anti-CD45-PE (-) and DAPI (+) cells were scored as a positive
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result. Anti-CD45-PE (+) and DAPI (+) cells were identified as white blood cells (WBCs).
Example images are shown in Figure 4.12.

Figure 4.12. Fluorescence images of captured cells. (a) LNCaP cells were first identified
with anti-CK-FITC (green) and white blood cells were identified with anti-CD45-PE
(red). (b) Cell nuclei were stained with DAPI. (c) Shows the merged image of panels (a)
and (b). Images were artificially enhanced for clarity.
For these experiments, four different conditions were tested (Figure 4.13) using the
diluted blood sample. The first condition (Group 1) involved spiking ~54 LNCaP cells and
1.25 nM (100 ng/mL) of PSMA. Group 2 represents a sample containing ~27 spiked
LNCaP cells and 50 pM (4 ng/mL) of spiked PSMA. Group 3 contained only ~27 LNCaP
cells. Group 4 was used as a control containing no added target protein or added cells. It
should be noted that the spiked PSMA concentrations provided are relative to the 1 mL
diluted sample volume.
The results shown in Figure 4.13 reveal several important features of the new device.
First, for all conditions where LNCaP cells were added, a consistent detection efficiency
of ~90% was obtained. This was true for both quantities of cells (i.e. 27 and 54 cells per 1
mL of diluted blood) as well as both concentrations of spiked PSMA (i.e. 50 pM and 1.25
nM) and is not significantly different from that achieved using culture media (~93%). The
zero detected cells in the control samples (Group 4) further indicates that the increased
captured cell purity (i.e. the enhanced visualization of cells), due to the separation of
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protein-bound beads and free-beads afforded by the micro-aperture chip, led to the
elimination of any false-positive results. However, ~200 WBCs were also observed on the
micro-aperture chip surface after each detection. This is likely the result of non-specific
binding of WBCs via three mechanisms: (1) WBCs from blood adhering to the chip surface.
(2) WBCs non-specifically binding to the magnetic beads in blood during incubation which
are then attracted to the chip surface. (3) WBCs expressing small amounts of surface
antigens and are thus captured by the anti-beads. To put this observation into perspective,
using a conservative estimate, 250 µL of whole blood contains over ~1 million WBCs
[127]. Thus, the device was able to remove more than 99.9% of endogenous leukocytes.
For PSMA, the measured concentration for Group 3 and Group 4 were nearly identical
(both were approximately 0.39 nM (31 ng/mL)) which revealed that the presence and
capture of LNCaP cells did not interfere with free-protein detection. The 0.39 nM measured
PSMA concentration for the diluted sample is also consistent with previous studies using
healthy human blood [125, 126]. Spiking a PSMA concentration of 50 pM into the diluted
sample (Group 2) was found to be significantly different from the PSMA measured
concentrations for Groups 3 and 4 (p < 0.05). This appears to represent the lowest
detectable concentration above background using this device coupled with the fluorescence
quantification method utilized in this work. The lowest detectable concentration from
diluted blood (50 pM) in Figure 4.13 is larger than the lowest detectable concentration from
culture media in Figure 4.10 (12.5 pM). The difference in sensitivities is likely due to
matrix affects (e.g. non-specific binding) which usually increases the background noise of
the assay. However, this did not appear to affect cell capture yields. Lastly, the difference
in the measured concentration of PSMA from Group 1 compared to Groups 3 and 4 (a

111
difference of 1.31 nM) is similar to the theoretical difference in the spiked concentration
(1.25 nM). This indicates that higher concentrations of target protein are still efficiently
captured even when simultaneously detecting cells.

Figure 4.13. The detection yield of LNCaP cells and the measured concentration of freePSMA obtained from diluted healthy human blood (1:3, Blood:PBS). Grey columns
represent the cell detection yield while the orange columns represent the measured PSMA
concentration as determined from Equation (4.1). Zero cells were detected for Group 4.
The number of LNCaP cells spiked in Groups 1, 2, 3, and 4 were approximately 57, 27,
27, and zero, respectively. The concentrations of PSMA spiked in Groups 1, 2, 3, and 4
were 1.25 nM, 50 pM, 0 nM, and 0 nM, respectively. Error bars indicate one standard
deviation for three measurements.
While the quantity of spiked LNCaP cells analyzed in Figure 4.13 falls into the expected
numbers of CTCs observed in prostate cancer patients (0 – 400 CTCs per mL of whole
blood), we also challenged the new device by performing dual detection at the lower end
of this range. In order to detect (and accurately aliquot) a small number of target cells using
conditions as similar as possible to that in Figure 4.13, a larger volume of blood was
necessary. Here, 1 mL of whole blood was diluted with PBS (to 4 mL), spiked with ~20
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LNCaP cells and 50 pM of PSMA, and then incubated on an end-over-end rotator to
homogenize the sample. The solution was then split into 4 – 1 mL tubes and each was
individually analyzed as above. A control sample without added PSMA or target cells was
also tested. The results revealed that the number of LNCaP cells captured in consecutive
tubes was 4, 6, 4, and 3 cells, which compared to zero cells detected in the control – the
theoretically expected result was 5 cells per tube. Due to the stochastic distribution of a
small number of cells in the 4 mL sample, the capture yield was calculated by summing
the four individual tubes, revealing an 85% detection efficiency. For free-PSMA, the
concentration in the four tubes was uniformly distributed and was significantly different
from the non-spiked control (a difference of ~80 pM, consistent with Figure 4.13).
Collectively, these results show the great potential of the micro-aperture device for dual
detection of cell and protein targets from clinical samples.
4.4

Conclusions

In Chapter 4, we presented a dual-chamber, immuno-magnetic device capable of
the simultaneous detection of cellular and molecular biomarkers of prostate cancer.
The micro-aperture chip design provided affinity- and size-based separation of
targets while enabling highly efficient capture of cells and proteins from a single
sample fluid. The new platform yields cells in greater purity (i.e. the elimination of
protein-bound or free magnetic beads), improves multi-ligand targeting by allowing
for higher bead concentrations to be used in an assay, and enables further
downstream analysis of captured analytes. Two types of prostate cancer biomarkers,
free-PSMA protein and LNCaP cells, were measured and used to characterize the
device. The results demonstrated a 34 pM LOD of PSMA spiked into culture media.
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The detection yield of LNCaP cells was found to be independent of the PSMA
concentration using a mixture of antibody beads against different cell markers, and
to be consistently near ~93%. The dual measurement of PSMA and LNCaP cells
was further demonstrated from diluted healthy human blood to mimic an actual
cancer patient sample. For these experiments, the cell detection yield was 85 – 90%,
independent of the spiked PSMA concentration. The lowest detectable PSMA
amount was found to be 50 pM for the diluted blood sample. The capability to
simultaneously detect protein and cellular targets combined with the ability to extract
desired rare cells for further investigation illustrates the potential of this device for highthroughput analysis of clinical samples. In the future, we expect this system to be highly
useful for a broad variety of applications including dual detection of CTCs and cell-free
DNA.
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CHAPTER 5. APPLICATIONS AND FUTURE WORK

5.1

Introduction

The previous chapters have introduced and demonstrated the performance of two
generations of a fluidic system capable of simultaneously detecting molecular and cellular
biomarkers. The significance of the second-generation platform for application in the clinic
was initially presented (Chapter 3) as a means of sensitively detecting and quantifying
CTCs in NSCLC and PANC blood samples. In this chapter, we extend the potential of our
device by further showing its ability to cultivate captured tumor cells. Future work will
then focus on utilizing the isolated CTCs for downstream single-cell genetic analysis and
mutation identification, the advancement and implementation of novel capture ligands
(aside from antibodies) for improving assay performance, and correlating captured CTCs
with specific protein biomarkers in actual patient samples. These applications demonstrate
the ability of the micro-chip system to integrate the simultaneous and sensitive detection
of multiple biomarkers (cells and proteins/molecules), which can be used for monitoring
cancer treatment, with advanced single-cell analysis techniques and biomarker discovery.
5.2

Post-detection Application: Cultivation of Captured Cells

While the ability to utilize the second-generation platform for achieving high
volumetric blood sample through-put and the sensitive capture of CTCs from patient
blood is important in and of itself, the capability to further cultivate these captured
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CTCs would provide additional and valuable information about the disease – such
as the response to certain cancer drug treatment regimens. However, this requires
not only sensitive cellular detection but also the subsequent ability to release the
captured cells as viable analytes for downstream culturing. In order to demonstrate
this potential, preliminary experiments were conducted.
Here, tumor cells (~100 MCF-7 cells) were first spiked into culture media (1 mL)
and then captured with the device (see Chapter 3 for procedural details). Following
detection and the elimination of free beads from the chip surface, the bottom magnet
was removed and the subsequent injection of PBS allowed the captured cells to be
collected at the pump outlet, in a petri dish. A bright-field image of the retrieved
cells is shown in Figure 5.1 (a). While this ability to easily obtain the captured cells
from the device allows one to perform numerous types of analyses, such as cell
enrichment or DNA/RNA isolation, we chose to investigate the susceptibility of the
cells in culture. Thus, the growth of the cells in an incubator was monitored over
several days and is shown in Figure 5.1 (b-e). Initially, the results revealed that the
bead-bound cells first settled down and attached to the petri dish surface on day 0.
However, from day 1 onwards, the cells began to grow and divide – an indication of
their viability – with a morphology that was similar to that of the parental cell line
prior to the experiment. A follow up experiment conducted using captured KB cells
spiked into a blood sample yielded similar results.
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Figure 5.1. Post-detection retrieval and growth of MCF-7 cells. (a) Cells retrieved from
the micro-aperture chip and placed in a petri dish. (b)–(e) Cell growth from day 1 to day
5.

This preliminary evidence suggests that the use of antibody conjugated beads with
the micro-chip device for the capture of rare tumor cells has the potential for
enabling their release and subsequent cultivation under suitable environmental
conditions. However, additional characterization will be necessary to further verify
that the growth of the captured cells is similar to the parental line, from a molecular
level. As CTCs are such a rare occurrence in a patient blood sample, the feasibility
and reproducibility for cultivating single cells or small numbers of cells will also be
investigated.
5.3
5.3.1

Future Work
Single Cell Analysis

As the ability to grow cultures of captured cells is desirable, an additional advantage of
whole cell detection enabled by the second-generation device is the ability to perform other
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types of downstream assays using only single-cells. For example, a captured cell can be
aspirated from the device, lysed, and then subjected to high-throughput DNA/RNA
sequencing to obtain valuable information. This includes the discovery of genetic
mutations which could then be translated to the clinic as a novel biomarker, the elucidation
of intrinsic tumor biology, and providing new targets to aid in the development of
therapeutics. In a recent study by Chen et al. involving single CTC analysis, the authors
found that captured tumor cells that express genes relate to the epithelial–mesenchymal
transition are strong predictors of metastatic prostate cancer [128]. This illustrates the
potential value of the information that can be uncovered via the deeper examination of
captured CTCs enabled using our device.
While advances in high-throughput DNA/RNA sequencing enable one to obtain wholegenome level information from a small number of cells, it has a high requirement: the
captured cells need to be as pure as possible and should be devoid of endogenous
analytes/cells present in the original blood sample. While the second-generation platform
enables more than 99.9% of WBCs to be removed when capturing the rare CTCs on the
chip surface, the small number of remaining normal cells constitute a background that
makes it difficult to extract genomic information from the few tumor cells present. In order
to meet this high requirement and achieve single-cell level DNA/RNA analysis using the
micro-chip device, we plan to first perform a round of CTC isolation and then follow-up
this process with single-cell aspiration as demonstrated in Figure 5.2 using a micro-pipette
to selectively withdraw a single-cell and move it to a collection tube. The retrieved and
processed cells will be delivered to our collaborators, cancer biologists and clinical
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oncologists at the Indiana University Medical School, who will work with us to explore
the genetic analysis of captured single tumor cells from cancer patient samples.

Figure 5.2. Schematic for single-cell CTC analysis using the micro-chip device. (a)
Detected cells are first washed out of the device and onto an exposed surface. (b) Singlecells are then selectively isolated using a micro-pipette and placed into a collection tube
for downstream genetic analysis (c).
5.3.2

Integration of Novel Ligands for CTC Detection

As mentioned throughout this thesis, the use of antibody conjugated magnetic beads with
the two generations of devices enabled high efficiency capture of target analytes – cells
and molecules. However, while antibodies have many positive attributes, such high
specificity and affinity constants, the use of protein capture agents also has several
disadvantages. These

include variability associated with immobilization

(e.g.

biotinylation), high cost, as well as being prone to denaturation, among others [129]. For
these reasons, there has been a push to develop cheaper and more stable targeting ligands
which can simultaneously achieve similar levels of specificity and binding kinetics [64].
As the micro-chip device is ideally suited for rapidly analyzing large volumes of samples
incubated with ligand conjugated magnetic beads, the investigation of alternative
molecules which target many different biomarkers (i.e. multiple cell surface receptors
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and/or free-protein molecules) can be easily conducted. We currently have an ongoing
collaboration with Prof. Phillip Low’s group at Purdue University in which we are testing
the feasibility of applying newly synthesized small-molecule targeting compounds for
capturing folate+ tumor cells. We plan to continue this work and soon apply the outcome
to CTC detection from ovarian cancer patients while using the captured cells for testing
novel therapeutics in vitro.
5.3.3

Patient Blood Test

Lastly, as our device represents a unique ability for high-throughput sample analysis and
sensitive CTC detection, we plan to continue our collaboration with multiple research labs
at the Indiana University Medical School for the detection of tumor cells from cancer
patient samples. This will help to better understand the correlation between CTC count and
a patient’s disease state or treatment progression.
Additionally, we also demonstrated the ability to simultaneously detect cellular and
molecular biomarkers from a single sample. This is important for aiding the development
of new biomarker panels that can provide a more specific and accurate patient diagnosis –
based on a combination of large (e.g. cells) and small (protein) target analytes – as well as
to help uncover new mechanisms of the underlying biology of a disease. A good example
of this limitation involves the over reliance in prostate cancer diagnosis on the
concentration of only measured PSA levels in blood – an analysis which could be made
more reliable by simultaneously detecting CTCs and regularly monitoring the observed
correlation during patient visits. We plan to test this hypothesis in a future cancer patient
investigation.
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5.4

Summary

As cancer has been shown to be increasingly heterogeneous, the ability to perform
multiplexed analysis of biomarkers has become ever more important in the diagnosis of a
patient’s disease state. In this thesis, we presented two generations of devices which
enabled us to achieve the concurrent detection of both cellular and molecular target
analytes from a single blood sample. In the development of the first-generation system
(Chapter 2), a single chamber fluidic device captured and quantified both large (cells) and
small (free-proteins) targets on the same detection surface. This platform subsequently
enabled the simultaneous detection of two analytes using ascites fluid from an ovarian
cancer patient. While this first-generation device achieved the capability of concurrent
detection, it suffered from the inability to measure the large and small targets without
mutual interference, while also limiting the number of antibody beads which could be used
in an experiment – an important experimental condition for achieving highly efficient
capture of extremely rare target cells.
In order to further improve the performance of the dual detection modality, we designed
a second-generation device which could physically size-separate cellular and molecular
targets into upper and lower chambers, respectively, via the use of a silicon chip containing
micro-apertures (Chapters 3 and 4). This system enhances the captured cell purity, allows
the separate retrieval of captured cells and proteins for downstream analysis, and enables
higher bead concentrations for improved multiplexed ligand targeting. By initially focusing
on only CTC capture, the second-generation device was applied to the successful detection
and enumeration of CTCs from blood samples of cancer patients and demonstrated the
ability to correlate cancer treatment with tumor cell count. In Chapter 4, we demonstrated

121
the dual detection capability of the micro-aperture chip system by simultaneously detection
two targets spiked into healthy human blood, thus illustrating its clinical potential.
A key benefit of the second-generation system involves the ability to retrieve detected
target cells for downstream analysis. Thus, we were able to demonstrate this feature and
show the viability of captured cells by successfully culturing them off-chip. Future work
will involve working with collaborators to perform genetic analysis for mutation
identification using CTC single-cells detected from cancer patients, to develop and validate
novel targeting ligands (as a replacement for antibodies), and to aid in the development of
new biomarker panels. Due to its versatility, robustness, relative architectural simplicity,
and compatibility with existing practices, we envision the second-generation platform to
be highly beneficial in clinical and research settings.
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APPENDIX
MATLAB codes for B-ratio calculation
clear all;
clc;
%file path set
cd('FLIE PATH');

%get fluorescent image file
[file_name,file_path] = uigetfile('*.jpg', 'Pick a FL file'
I = imread([file_path, file_name]);
%convert RGB image to Gray scale and save as a M*N matrix
tg1 = I(:,:,2);
%get the size of entire pic
[width length] = size(tg1);

%sub window
re_point_s = [101 101];
re_point_e = [width-100 length-100];
%caculate the total intensity of FL
g = uint8(zeros(re_point_e(1)-re_point_s(1)+1, re_point_e(2)re_point_s(2)+1));
r = tg1(re_point_s(1):re_point_e(1), re_point_s(2):re_point_e(2));
b = uint8(zeros(re_point_e(1)-re_point_s(1)+1, re_point_e(2)re_point_s(2)+1));
c1 = sum(r(:));
%save processed FL image
imwrite(r, ['FL_gray_',file_name]);
%BF image processing
c2 = Image_processing_nor();
%calculate B-ratio
Ans = c1/c2;
%end
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